In Vivo Functional Consequences of the Fully Edited 5-HT2C-VGV Receptor by Olaghere da Silva, Uade
IN VIVO FUNCTIONAL CONSEQUENCES OF THE FULLY EDITED 5-HT2C-VGV 
RECEPTOR 
By 
Uade Brimmy Olaghere da Silva 
Dissertation 
Submitted to the Faculty of the 
 Graduate School of Vanderbilt University 
 in partial fulfillment of the requirements 
 for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Neuroscience 
MAY, 2010 
Nashville, Tennessee 
Approved: 
Professor Craig Kennedy 
Professor Randy Blakely 
Professor Sanika Chirwa 
Professor Ariel Deutch 
Professor Elaine Sanders-Bush  
ii 
 
TO 
 
 My mother Maria JP da Silva without whom none of this would be possible 
My father for teaching me discipline 
 My older sister Omiome for setting the example 
My younger siblings Ajibade and Ajima for their fiery passion and boundless 
love 
Philip Slatkin for words of wisdom, for excelling at a thankless job 
Anthony Bryant for P.V.E.T.C 
Omiome for picking me up off the floor 
Amos Akasa for being the definition of a friend 
Omiome for putting me on the path 
Dr. Christine Hohmann for taking me in 
Morgan State University and the MBRS R.I.S.E program 
Dr. Rita Barrett for helping get my feet wet 
Dr. Randy Nelson for giving me a chance 
Neville Hodge for inspiration, motivation, guidance, adopting yet another lost 
child, and leading me through some of the best years of my life 
iii 
 
Mark Moody for teaching me to trust myself 
All my teammates for joyful bus rides, painful practices, and lasting friendships 
Sherell for showing me the price of failure 
Danah Jack for teaching me ambition 
Hugh Fentress for caring 
Anthony Blount for perspective 
Dr. Elaine Sanders-Bush for infinite patience and guidance 
Rhonda for love and understanding beyond comprehension 
Maria da Silva for the impossible and most difficult job in the world 
  
iv 
 
ACKNOWLEDGEMENTS 
 
This work is the result of the efforts of many, whom I would like to acknowledge.  
  My mentor and friend Dr. Elaine Sanders-Bush, who adopted and 
nurtured a stray kitten. 
  Kathleen Patterson, whose contribution to simplifying my work and  my 
life is immeasurable, without her tireless efforts, early mornings, and unmatched 
dedication  this work would not be what it is.  
 Mike Morabito and Ron Emeson who generated the VGV transgenic mice, 
and generously provided me with breeding pairs. 
 I am extremely grateful to all the members of the Sanders-Bush Lab, 
whose experience, knowledge, guidance and camaraderie played a large role in 
the completion of this work. 
 The financial support of Vanderbilt University and the N.I.H. without which 
this work would not be possible. 
 Finally I need to acknowledge the contributions of the rats and mice, 
without their sacrifice this work would have been impossible. It is a debt I will 
never be able to repay. 
 
 
v 
 
TABLE OF CONTENTS 
 
Page 
Dedication .............................................................................................................ii 
Acknowlegements ................................................................................................iv 
List Of Tables ..................................................................................................... viii 
List Of Figures ......................................................................................................ix 
List Of Abbreviations ............................................................................................xi 
Chapter I: Introduction ....................................................................................... 1 
SEROTONIN: FUNCTION AND HISTORY ........................................................... 1 
SEROTONIN RECEPTOR SUBTYPES ................................................................ 5 
5-HT2 RECEPTORS .................................................................................... 7 
5-HT2A Receptor ........................................................................................... 7 
5-HT2B Receptor ........................................................................................... 8 
5-HT2C Receptors ................................................................................... 11 
5-HT2C Receptor Signal Transduction ........................................................ 11 
5-HT2C Receptor Distribution ...................................................................... 12 
Constitutive Activity of The 5-HT2C Receptor .............................................. 14 
In Vivo Function of 5-HT2C Receptors......................................................... 14 
Genetic Variation of 5-HT2C Receptors ....................................................... 15 
Single Nucleotide Polymorphisms .............................................................. 16 
vi 
 
Coding SNPs of the 5-HT2C receptor .......................................................... 18 
RNA Editing of the 5-HT2C Receptor ........................................................... 20 
Distribution of 5-HT2C Receptor mRNA Isoforms ........................................ 24 
Effects of 5-HT2C Receptor Editing in vitro .................................................. 24 
5-HT2A Receptor vs. 5-HT2C Receptor ........................................................ 28 
Specific Aims ......................................................................................... 29 
Chapter II: Ligand Specificity in Mice ............................................................. 34 
Introduction ........................................................................................... 34 
MATERIALS AND METHODS ....................................................................... 35 
Animals ....................................................................................................... 35 
Drugs and Radioligands ............................................................................. 36 
Radioligand Binding .................................................................................... 36 
EEDQ Receptor Inactivation Protection Assay ........................................... 38 
Results and Discussion ......................................................................... ..38 
Competition Binding ................................................................................... 38 
EEDQ Inactivation Protection Assay .......................................................... 39 
Predictably Manipulating 5-HT2C receptor mRNA editing ........................... 39 
Chapter III: In Vivo Function of the 5-HT2C-VGV Receptor ............................... 49 
Introduction ........................................................................................... 49 
MATERIALS AND METHODS ....................................................................... 51 
Animals ....................................................................................................... 51 
Drugs and Radioligands ............................................................................. 53 
vii 
 
GTP-sensitive High-affinity Agonist Binding in Membranes ........................ 53 
 [125I]-DOI and [3H]-Mesulergine Autoradiography ...................................... 55 
5HT2C  Receptor Agonist Impact On Locomotor Activity ............................. 57 
Biogenic Amine Levels ............................................................................... 57 
[3H]-Mesulergine Saturation Binding In Membranes ................................... 58 
Results ................................................................................................. 59 
5HT2C-VGV Receptors Exhibit Undetectable High Affinity Agonist Binding ... 59 
5HT2C-VGV Receptors in Brain Exhibit Low Agonist High Affinity Binding .... 64 
VGV/Y And VGV/X Mice Show Increased Sensitivity To Agonists ............. 64 
VGV/Y Mice Show Massive Increases In 5HT2C Receptor Density ............. 68 
VGV/Y Mice Show Large Increases In 5-HT2C Receptor Autoradiography . 71 
Biogenic Amine Levels ............................................................................... 75 
Discussion ............................................................................................ 78 
Chapter IV: Conclusions and New Questions ................................................ 84 
Summary and Future Directions ............................................................... 84 
Implications for Human Studies .................................................................. 85 
Increased 5-HT2C-VGV Receptor Density ...................................................... 86 
Inverse Agonist / Antagonist Induced Hyperactivity .................................... 88 
Opposing Locomotor Effects Of Various Ligands ....................................... 89 
Mice Are Not Rats ...................................................................................... 90 
Conclusion ............................................................................................ 95 
References ........................................................................................... 97 
  
viii 
 
LIST OF TABLES 
 
Table .............................................................................................................. Page 
1. Serotonin Family Of Receptors .................................................................. 6 
2. Evidence for 5-HT2C Receptor RNA Editing in Human Brain Disorders ... 25 
3. Affinity (Ki nm) Of Various 5-HT2 Ligands At Human Receptors .............. 33 
4. 5-HT2 Ligand Affinities Across Species .................................................... 40 
5. Biogenic Amine Levels In Frontal Cortex And Striatum After Saline And 
SB206553 Administration ........................................................................ 76 
 
  
ix 
 
LIST OF FIGURES 
 
Figure ............................................................................................................ Page 
1.SYNTHESIS AND DEGRADATION OF SEROTONIN (5-HT) .................................. 3 
2.SEROTONERGIC PROJECTIONS .................................................................. 4 
3. INTRACELLULAR SIGNALING CASCADE OF THE 5-HT2C RECEPTOR .................. 9 
4. MUTIPLE SIGNALING CASCADES OF THE 5-HT2A/2C RECEPTOR ....................... 10 
5. EXTENDED TERNARY COMPLEX MODEL ................................................... 13 
6. 5-HT2C RECEPTOR GENE AND MRNA STRUCTURE ..................................... 19 
7. 5-HT2C RECEPTOR AMINO ACID MUTATIONS ................................................... 22 
8. 5-HT2C RECEPTOR EDITING SITES .......................................................... 23 
9. 5-HT2C MRNA ISOFORM DISTRIBUTION IN JAX® 129S1 MICE ...................... 26 
10. RNA EDITING CHANGES EC50 VALUES FOR PI HYDROLYSIS ........................ 27 
11. AGONIST ACTIVATION OF 5-HT2C RECEPTORS ......................................... 31 
12. 5-HT2C EDITING ELIMINATES HIGH AFFINITY AGONIST BINDING ................. 32 
13. M100907 COMPETITION BINDING ........................................................ 41 
14. SPIPERONE COMPETITION BINDING ....................................................... 42 
15. SB206553 COMPETITION BINDING ....................................................... 43 
16. EEDQ IRREVERSIBLY INACTIVATES 5-HT2A RECEPTORS ........................... 44 
17. EEDQ INACTIVATION PROTECTION ASSAY METHODS ................................ 45 
18. EEDQ  DOSE RESPONSE AT 5-HT2A RECEPTORS .................................... 46 
19. EEDQ IS INEFFECTIVE AT 5-HT2C RECEPTORS....................................... 47 
x 
 
20. SB206553 DOES NOT OCCUPY 5-HT2A RECEPTORS ............................... 48 
21. AGONIST HIGH AFFINITY BINDING: MEMBRANES FROM WT MICE ............... 60 
22. AGONIST HIGH AFFINITY BINDING: MEMBRANES FROM VGV/Y MICE ......... 61 
23. GTP SENSITIVE BINDING [125I]-DOI BINDING ......................................... 62 
24. GTP SENSITIVE [3H]-MESULERGINE BINDING ......................................... 63 
25. AGONIST HIGH AFFINITY BINDING: AUTORADIOGRAPHY ............................. 66 
26. MK212 DOSE-DEPENDENT INDUCTION OF HYPOLOCOMOTION .................. 67 
27. 5-HT2C RECEPTOR DENSITY IN VGV/Y AND VGV/X MICE ...................... 69 
28. 5-HT2C RECEPTOR DENSITY IN INI/Y MICE ............................................ 70 
29. VGV/Y [3H]-MESULERGINE AUTORADIOGRAPHY ..................................... 72 
30. INI/Y [3H]-MESULERGINE AUTORADIOGRAPHY ....................................... 73 
31. REGIONAL 5-HT2C RECEPTOR DENSITY ................................................. 74 
32. SB206553 INCREASES DOPAMINE TURNOVER IN VGV/Y MICE ................ 77 
33. SB206553 INDUCED HYPERLOCOMOTION ............................................. 91 
34. DA RECEPTOR ANTAGONISM POTENTIATES SB206553 INDUCED 
HYPERLOCOMOTION ................................................................................ 92 
35. INCREASED BINDING IN KAWAHARA MICE: AUTORADIOGRAPHY ................... 93 
36. OPPOSING EFFECTS OF LIGANDS IN WILD TYPE VS. VGV/Y MICE ............. 94 
  
xi 
 
LIST OF ABBREVIATIONS 
 
5-HT   Serotonin, 5-hyroxytryptamine 
CNS   Central nervous system 
DAG   Diacyl glycerol 
DIC   Differential interference contrast 
DMEM  Dulbecco’s modified Eagle’s medium 
DOI   (±)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane 
EC50 Concentration of drug that gives 50% of the maximal 
response 
EEDQ   N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
GDP   Guanosine 5′-diphosphate 
G-protein  Guanine nucleotide binding protein 
GPCR   G-protein coupled receptor 
GppNHp  5'-(β,γ-imido)triphosphate 
GTP   Guanosine 5′-triphosphate 
IP3   Inositol 1,4,5-triphosphate 
LSD   Lysergic acid diethylamide 
xii 
 
mCPP   m-chlorophenylpiperazine 
PI hydrolysis  Phosphatidylinositol hydrolysis 
PIP2   Phosphatidylinositol 4,5-bisphosphate 
PLA2   Phospholipase A2 
PLC   Phospholipase C 
PLD   Phospholipase D 
PKC   Protein kinase C 
SNP   Single nucleotide polymorphism 
TM   Transmembrane domain
1 
 
Chapter I: Introduction 
 
Serotonin: Function and History 
 
 The indolamine neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) 
was isolated as a vasoconstrictor released from platelets (Rapport et al., 1948) 
and subsequently named  by Maurice Rapport, Arda Green and Irvine Page of 
the Cleveland Clinic. The synthesis and metabolism of 5-HT, summarized in 
Figure 1, has been extensively studied since the first demonstration of 5-HT in 
brain (Erspamer 1952).  5-HT is synthesized from the amino acid tryptophan, 
which is acted upon by the rate limiting enzyme tryptophan hydroxylase.  Brain 
tryptophan hydroxylase is not saturated, nor regulated by end product inhibition; 
as a result, the amount of tryptophan in the brain influences the synthesis of 5-
HT.  The product of this reaction, 5-hydroxytryptophan, is then metabolized by L-
amino acid decarboxylase to form 5-HT. Monoamine oxidase (MAO) is the 
enzyme involved in the principal route of degradation of 5-HT; it acts on 5-HT to 
form 5-hydroxyindole acetic acid (5-HIAA) through a 2-step process (Figure 1). 5-
HT action is also terminated by Na+ dependent active uptake by the 5-HT 
transporter, localized in the outer membrane of pre-synaptic serotonergic axon 
terminals and in platelets. 5-HT is found in enterochromaffin cells throughout the 
gastrointestinal tract and in platelets, as well as in specific regions of the CNS. 
Cell bodies of serotonergic neurons are localized in brainstem midline raphe 
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nuclei. Serotonergic axon projections are widely distributed throughout the brain 
and spinal cord (Figure 2). 5-HT's primary role is modulation of neural 
transmission. At the systems level it plays a role in a great deal of physiologic 
and cognitive functions such as, sleep, learning and memory, temperature 
regulation, aggression , appetite, motor behavior, cardiovascular and 
gastrointestinal function (Lentes et al., 1997; Heisler, 2000). 5-HT dysfunction 
has been implicated in an array of brain disorders including, depression, 
schizophrenia, and obsessive compulsive disorder, for example (Breier, 1995). 5-
HT is able to achieve promiscuous modulation of these wide ranging effects 
through activation of a large family of 5-HT receptors. 
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5-Hydroxytryptophan 
5-Hydroxyindole Acetaldehyde 
5-Hydroxytryptophol 
Tryptophan 
hydroxylase* 
amino acid 
decarboxylase 
aldehyde reductase aldehyde 
 
Monoamine Oxidase 
 
Figure 1. Synthesis and Degradation of Serotonin (5-HT). 
The amino acid L-tryptophan is synthesized into 5-HT via the rate limiting 
enzyme tryptophan hydroxylase. The major metabolite of 5-HT is 5-HIAA. 
S10ynthesis and degradation enzymes are highlighted in blue.  
5-Hydroxyindole Acetic Acid 
(5-HIAA) 
5-Hydroxytryptamine 
(Serotonin, 5-HT) 
L-Tryptophan 
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Figure 2: Serotonergic Projections 
Serotoninergic projections from the brain stem raphe nuclei (blue ovals) 
innervate the CNS 
To Spinal cord 
Thalamus 
Striatum 
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Serotonin Receptor Subtypes 
 
 Fourteen structurally and pharmacologically distinct receptors are 
classified into seven receptor families (5-HT1 to 7).  This scheme originally 
proposed by Humphrey et al (1993), remains largely unchanged (Table 1). One 
member of the receptor family, the 5-HT3 receptor is a ligand-gated ion channel, 
the remaining members are seven transmembrane spanning , G-protein coupled 
metabotropic receptors; each comprised of three extracellular and three 
intracellular loops.  The intracellular loops are critical for receptor interaction with 
heterotrimeric GTP-binding proteins (G-protein), which initiates signal 
transduction. The different receptor families are distinguished primarily by their 
downstream effectors (Table 1) (See Barnes and Sharp, 1999 for review).  The 
5-HT1 family of receptors consists of 5 receptor subtypes all linked to inhibition of 
adenylate cyclase; through coupling to the Gi/o family of G proteins (Limbird, 
1988). The 5-HT1A receptor is localized in raphe cell bodies where it inhibits cell 
firing. The 5-HT1B/D receptor functions as an autoreceptor and inhibits neuronal 5-
HT release. 5-HT4 receptors which are distributed throughout the body, activate 
adenylate cyclase, leading to a rise in cyclic AMP (Hegde and Eglen, 1996). 5-
HT6 and 5-HT7 receptors are also linked to activation of adenylate cyclase.  
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Table 1: Serotonin Family of Receptors 
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5-HT2 Receptors 
 
 Of particular interest to our laboratory is the 5-HT2 family of receptors, 
which encompasses three receptor subtypes, 5-HT2A, 5-HT2B and 5-HT2C. The 
classical signal transduction pathway for these receptors is Gαq-coupled 
activation of phospholipase C (PLCβ), cleaving phosphotidylinositol bisphosphate 
(PIP2) into diacylglycerol (DAG), which activates protein kinase C (PKC) and 
inositol triphosphate (IP3), which promotes intracellular calcium release (Figure 
3). 5-HT2 receptors also couple to other G-proteins (G12/G13 and Gi/o) to activate 
additional signaling cascades (Figure 4).  
 
 The 5-HT2A receptor was initially observed in cortical membranes derived 
from rat. It was detected as a binding site with high affinity for the dopamine 
antagonist [3H]-spiperone, but with a pharmacological profile more consistent 
with a 5-HT receptor (Leysen et al., 1978; Peroutka and Synyder, 1979).  The 5-
HT2A receptor has been shown to be a key target of hallucinogenic drugs. While 
most hallucinogens have affinity for the 5-HT2C receptor as well, drug 
discrimination studies have demonstrated that discriminative stimuli elicited by 
hallucinogenic drugs are dependent on 5-HT2A receptor activation (See Winter, 
2009; Fantegrossi et al., 2008).  Autoradiography and immunocytochemistry 
have been used to map 5-HT2A receptor distribution. Receptor autoradiography 
studies, usually employing "selective" antagonists, localized high binding site 
5-HT2A Receptor 
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levels in cortical areas, caudate nucleus, nucleus accumbens, hippocampus and 
olfactory tubercle (Palacios and Dietl, 1988) . There is close concordance 
between  5-HT2A receptor binding sites, mRNA and immunoreactivity, which 
suggests that cells expressing these receptors are located in the same regions 
as the receptors themselves. Evidence also suggests that the 5-HT2A receptor is 
localized on GABAergic interneurons, cortical pyramidal neurons, and cholinergic 
neurons which supports its ability to modulate a variety of physiological 
processes. Activation of the 5-HT2A receptor has been shown to induce 
hyperactivity, head twitches in rodents, and visual hallucinations in humans. 
 
 The 5-HT2B receptor, originally found to mediate contractions of the 
stomach fundus in rats (Vane, 1959), is thought to be present in limited amounts 
in the mouse and human brain (Loric et al., 1992; Bonhaus et al., 1995).
5-HT2B Receptor 
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Figure 3: Intracellular Signaling Cascade of the 5-HT2C Receptor. 
Gq, heterotrimeric G protein subunit; PIP2, phosphatidylinositol-1,4-bisphosphate; IP3, inositol-1,4,5-triphosphate; DAG, 
diacylglycerol; PKC, protein kinase C 
  
 
10 
Figure 4: Mutiple Signaling Cascades of the 5-HT2A/2C Receptor. 
The 5-HT2A/2C receptor can activate multiple G-proteins, stimulating multiple pathways. PIP2, phosphatidylinositol-1,4-
bisphosphate; IP3, inositol-1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C; PLD, phospholipase D; PLA2, 
Phospholipase A2; cGMP, guanosine-3′,5′-cyclic monophosphate; AA, arachidonic acid 
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 The 5-HT2C receptor was initially observed as  a [3H]-serotonin binding site 
in the choroid plexus of various species. These binding sites could also be 
labeled with [3H]-mesulergine and [3H]-LSD, but not by [3H]-ketanserin, an 
antagonist ligand used to label 5-HT2A receptor binding sites (Pazos et al., 
1984a). Unlike the 5-HT2A receptor, the 5-HT2C receptor has a relatively high 
affinity for 5-HT, which led to it initially being classified as a member of the 5-HT1 
family of receptors. By 1991, the 5-HT2C receptor had been cloned in rat, mouse 
and human, which led to the reclassification of the receptor to the 5-HT2 family 
where it presently resides. The 5-HT2C receptor is X-linked (human chromosome 
Xq24, mouse chromosome X D-X F4); this means that males only express a 
single maternal allele of the gene. There is greater than 80% sequence 
homology between the human and mouse receptors in the transmembrane 
regions. The mouse receptor possesses six N-glycosylation sites (Yu et al., 
1991), four of these sites are also present in the human receptor (Saltzman et al., 
1991). 
5-HT2C Receptors 
 
 The 5-HT2C receptor couples to several G-proteins including Gq, G12, G13 
and G15 (Berg et al., 2005); this allows for 5-HT2C receptor mediated activation of 
a diverse array of signaling pathways. Activation of 5-HT2C receptors increases 
PLCβ activity (Sanders-Bush et al., 1988) via Gq activation (Figure 3; Chang et 
5-HT2C Receptor Signal Transduction 
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al., 2000). 5-HT2C receptors have also been shown to activate phospholipase D 
(PLD) (McGrew et al., 2002), ERK MAP Kinase (Werry et al. 2005) and PLA2 
(Berg et al., 1996) as well as other downstream secondary signals (Raymond et 
al., 2001; Hoyer et al., 2002). 5-HT2C receptor activation of PLD in choroid plexus 
is mediated by coupling to G13, and activation of the small G-protein Rho (Figure 
4). 5-HT2A receptor activation of PLA2, via a pertussis-toxin sensitive G-protein(s) 
(Kurrasch-Orbaugh et al., 2003), leads to the release of arachidonic acid from 
membrane phospholipids. It is likely that the 5-HT2C receptor shares similar 
properties. Arachidonic acid has several cellular functions of its own and is 
metabolized into an array of  bioactive compounds.  
 
 A variety of ligands have been used to map the distribution of 5-HT2C 
receptors throughout the CNS (Palacios et al., 1991b). Very high densities are 
detected in the choroid plexus of all species examined. 5-HT2C receptors are also 
localized in cortical areas, the limbic system (nucleus accumbens, hippocampus, 
amygdala) and the basal ganglia, although at a density far below than that of 
choroid plexus. Unlike other 5-HT2 receptors, studies have found no evidence for 
5-HT2C receptor expression outside of the CNS. 
5-HT2C Receptor Distribution 
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Figure 5: Extended Ternary Complex Model 
The Extended Ternary Complex Model allows for the receptor to spontaneously 
isomerize to an active state, R*, or to couple to G in the absence of ligand. The 
cooperativity factors (e.g., , ß) modify the isomerization constant, L, as well as the 
equilibrium association constants (Ka and Kg ) when these isomerizations occur for 
receptor occupied either by agonist or inverse agonist. 
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 What further separates the 5-HT2C receptor from the other members of its 
family is constitutive activity. Simply put this means that the receptor has the 
ability to couple to and activate G-proteins and downstream signaling cascades, 
in the absence of a ligand induced conformational change. Constitutive activity  
has been shown to occur at many GPCRs including the 5-HT2C receptor (Barker 
et al., 1994). Although originally described in vitro (Niswender et al., 1999; see 
Teitler et al., 2002 for review), constitutive activity has since been shown to play 
a role in vivo, based on the finding that a 5-HT2C receptor inverse 
agonist/antagonist enhances DA release (De Deurwaerdère et al., 2004). The 
ternary complex model of receptor-G-protein interactions was revised to predict 
that GPCRs have the capacity to change spontaneously from an inactive 
confirmation (R) to an active confirmation (R*). The R* conformation of a receptor 
is the conformation that allows for coupling to and activation of G-proteins 
(Samama et al., 1993; Perez et al., 1996; Figure 5). This model has been further 
revised more recently to account for newer concepts such as functional 
selectivity. 
Constitutive Activity of the 5-HT2C Receptor 
 
 Activation of 5-HT2C receptors is associated with a variety of behavioral 
responses such as hypophagia, anxiety, penile erection, hyperthermia and 
hypolocomotion (Koek et al., 1992). These agonist-induced behaviors are 
antagonized by the 5-HT2C inverse agonist/antagonist SB206553 (Kennett et al., 
In Vivo Function of 5-HT2C Receptors  
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1994b, 1996).  The 5-HT2C receptor has been shown to regulate release of both  
mesolimbic and mesocortical dopamine (DA). Activation of 5-HT2C receptors 
decreases DA release, the inverse agonist/antagonist SB206553 increases DA 
release (Alex and Pehek, 2007; De Deurwaerdere et al., 2004; Filip and 
Cunningham, 2003; Navailles et al., 2003). 5-HT2C receptor contributions have 
also been examined in genetically modified mice unable to express functional 5-
HT2C receptors. These mice display hyperphagia, obesity and an increased 
propensity for convulsions (Tecott et al., 1995). There is also evidence for 
increased compulsive behavior (Chou-Green et al., 2003a), changes in sleep 
behavior (Frank et al., 2002)  and in the response to stress (Chou-Green et al., 
2003b; Akana, 2008) in 5-HT2C receptor null mice. In addition, the 5-HT2C 
receptor null mice display a hyperactivity phenotype, as well as a decline in the 
energy cost of locomotor activity thought to contribute to the adult onset obesity 
(Nonogaki et al., 2003).  
 
The HTR2C gene (Figure 6) encodes for the 5-HT2C receptor. As noted 
above It is X-linked (human chromosome Xq24; mouse chromosome X D-F4), 
meaning that males possess a single maternal allele. The HTR2C gene contains 
six exons and five introns spanning at least 230 Kb of DNA. However, the coding 
region of the 5-HT2C receptor contains three introns as opposed to two introns in 
the 5-HT2A and 5-HT2B receptors. The complete cDNA consists of 4775 
nucleotides of which 728 are in the 5´-untranslated region, 1377 in the coding 
Genetic Variation of 5-HT2C Receptors 
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region, and 2670 in the 3´-untranslated region encoding a protein of 458 amino 
acids with an estimated mass of 53 kDa (Xie et al.,1996). The 5´ leader region 
comprises exon I, II, and a small portion of exon III. The 5-HT2C receptor cDNA 
coding region extends from the rest of exon III to exon VI (Fig. 5).  
 
 Single nucleotide polymorphisms (SNPs) are substitutions of the wild-type 
Single Nucleotide Polymorphisms 
nucleotide for a novel nucleotide within the genomic DNA. SNPs are the most 
common type of genetic variation and occur at a frequency greater than 1% 
(Wang et al., 1998). Within the coding region of a gene, SNPs that cause a 
change in the encoded amino acid (non-synonymous SNP) may have a 
deleterious consequence on protein folding. Such polymorphisms may produce 
an unstable conformation of the protein, resulting in retention in the endoplasmic 
reticulum and decreased plasma membrane expression (Wenkert et al., 1996). 
Alterations in the amino acid structure may also have significant consequences 
on the function of a protein. 
 SNPs that alter the primary protein structure of a G-protein coupled 
receptor could modify the binding pocket of the receptor, disrupting receptor-
ligand interactions, and thus changing the binding properties of ligands, both 
endogenous and exogenous, or the ability of the receptor to isomerize to the 
active form. Alternatively, non-synonymous SNPs may interfere with the G-
protein coupling region of the receptor, changing the kinetics of receptor-G-
protein interaction in either the ligand-activated or basal state of the receptor. 
 17 
 
SNPs in this region, as well as other intracellular regions, could also alter 
phosphorylation of the receptor or the binding of accessory scaffolding proteins 
necessary for internalization and desensitization of the receptor. Each of these 
problems would result in a diminished signal downstream of the receptor leading 
to altered, and possibly inappropriate, cellular response to stimuli. Other forms of 
variation include coding polymorphisms that do not alter the amino acid 
sequence (silent or synonymous), promoter polymorphisms and variable number 
of tandem repeat (VNTRs) in 5' and 3' untranslated regions (UTRs). However, 
the consequences of these polymorphisms have been more difficult to deduce. 
Most polymorphisms are synonymous or non-coding in nature. This is believed to 
occur because there is selection against non-synonymous polymorphisms in 
most genes due to the high likelihood of deleterious effect on protein structure 
and function. Gender can be a factor for polymorphisms that occur on genes of 
the X and Y chromosomes. SNPs and other mutations that occur in this region 
may have a gene dose-dependent effect in both males and females. 
 Clearly, the single copy of the X- or Y-chromosome in men can impact the 
frequency at which these SNPs occur among males. Additionally, the X-
chromosome also undergoes the phenomena of X-chromosome inactivation – 
the silencing of one copy of the X-chromosome. X-chromosome inactivation will 
not change the genotypic frequency of a polymorphism in females, but it can alter 
the phenotypic consequence of variability of the silenced gene.  
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 Two SNPs have been identified in the coding region of the 5-HT2C 
receptor, one converting a cysteine (Cys) to a serine (Ser) at amino acid codon 
23 (Lappalainen et al., 1995) and the other converting a threonine (Thr) to an 
alanine (Ala) at amino acid codon 419. The latter SNP was only found in one 
early onset obese patient and has not been confirmed. Still another SNP found in 
the dbSNP database, converts a leucine (Leu) to a valine (Val) at amino acid 
codon 4 (Figure 7). 
Coding SNPs of the 5-HT2C receptor 
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Figure 6: Human 5-HT2C Receptor Gene and Mrna Structure 
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 What further separates the 5-HT2C receptor from its cohorts is RNA 
editing; the 5-HT2C receptor is the only known GPCR to undergo post-
transcriptional pre-mRNA editing. First documented in 1986 (Benne et al., 1986), 
RNA editing describes a cellular process, other than splicing, that results in an 
mRNA sequence different than that  
RNA Editing of the 5-HT2C Receptor 
designated by its DNA (Gott and Emeson 2000). This process involves either 
modification, deletion or insertion of nucleotides at distinct editing sites. RNA 
editing of the 5HT2C receptor is carried out by a family of three enzymes called 
Adenosine Deaminases that Act on RNA (ADARs) which convert adenosines to 
inosines, hence altering the genetic code. In the 5-HT2C receptor this takes place 
at 5 adenosine residues, or editing sites termed A, B, C, D and E (Burns et al. 
1997; Niswender et al., 1999). These adenosines are located within codons 157, 
159, and 161 in the mouse (Du et al., 2006), which code for isoleucine, 
asparagine, and isoleucine (INI), respectively. Editing by ADARs results in 24 
possible protein isoforms of the 5-HT2C receptor, ranging from 5-HT2C-INI, the 
unedited isoform, to 5-HT2C-VGV, the fully edited isoform (Figure 8). Variation in 5-
HT2C receptor RNA editing has been implicated in a variety of neuropsychiatric 
disorders, including depression, bipolar disorder and schizophrenia (Dracheva et 
al., 2008a; Dracheva et al., 2003; Dracheva et al., 2008b; Gurevich et al., 2002; 
Iwamoto and Kato, 2008; Iwamoto et al., 2005; Niswender et al., 2001; Sodhi et 
al., 2001). The most consistent and reproducible finding is an increase in 5-HT2C 
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receptor mRNA editing found post-mortem in the prefrontal cortex of suicide 
victims (Table 2). Although editing is decreased in the prefrontal cortex of 
persons with schizophrenia, this is less robust and not reproducible. 
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Figure 7: 5-HT2C Receptor Amino Acid Mutations 
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Figure 8: 5-HT2C Receptor Editing Sites. 
The genomic and edited mRNA sequences and their corresponding amino acid sequences are shown. Editing sites are 
highlighted in red and blue. The receptor schematic highlights the editing region in the second intracellular loop.  
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 While it is not possible to selectively label individual protein isoforms, it is 
possible to quantify the proportion of individual mRNA isoforms in the brain. In 
mice, the most abundant isoform is VNV isoform which accounts for 
approximately 40% of the total 5HT2C receptor mRNA, the VSV isoform accounts 
for ~20% (Figure 9). Those two isoforms along with INI, INV, VNI, and VSI 
account for 80 to 90% of the mRNA. The remaining isoforms are rarely 
expressed, being observed at 0-3%. There are however, considerable strain 
differences in the editing profiles of mice (Englander et al., 2005; Hackler et al., 
2006).  In the human brain the VSV isoform is the most abundant in terms of 
mRNA at 38% percent (Niswender et al., 2001). This is significant considering 
that the VSV has been shown to result in reduced functionality of the receptor in 
cell culture (Niswender et al., 1999). 
Distribution of 5-HT2C Receptor mRNA Isoforms 
 
 
 A decade ago,  Colleen Niswender a graduate student in the laboratory of 
Ron Emeson at Vanderbilt, examined the effects of 5-HT2C receptor editing on 
receptor function in cell culture. Her work demonstrated that editing occurring at 
sites that encode for the second intracellular loop of the 5-HT2C receptor, has the 
potential to disrupt G-protein coupling and therefore signaling downstream of 5-
HT2C receptor activation. Her work and the work of others shows that the VSV 
isoform has four-fold reduced constitutive activity and a four-fold reduction in  
Effects of 5-HT2C Receptor Editing in vitro 
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Disorder Editing Pattern Reference 
Schizophrenia No Change Dracheva et al., 2003 
Schizophrenia Decreased B editing; increase INI isoform Sodhi et al., 2001 
Schizophrenia / Depression with 
suicide 
Increased editing at A&D editing Niswender et al., 
2001 
Suicide with mood disorders Increased E, decreased D site editing  Gurevich et al., 2002 
Suicide  Increased editing Dracheva et al., 2008 
Table 2: Evidence for 5-HT2C Receptor RNA Editing in Human Brain Disorders 
Postmortem association studies of 5-HT2C mRNA editing and various neurological disorders. Results are highly variable, 
however, the most consistently reproducible finding is increased editing in suicide victims regardless of associated 
neurological disorder. 
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Figure 9: 5-HT2C Mrna Isoform Distribution In JAX 129S1 Mice. 
Editing site (top), RNA (middle), and protein (bottom) isoform distribution in 129 mice. 
Courtesy of David Airey, Vanderbilt University 
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Figure 10: RNA Editing Changes EC50 Values for PI Hydrolysis 
EC50, effective concentration at 50% response; PI, Phosphoinositide (Niswender et al., 1999). 
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potency to initiate intracellular signaling cascades relative to the unedited INI 
isoform (Figure 10; Niswender et al.,1999; Wang et al., 2000; see also Burns et 
al., 1997; Fitzgerald et al., 1999; Herrick-Davis et al., 1999; Price and Sanders-
Bush 2000; Visiers et al., 2001; Berg et al., 2001;Price et al., 2001; McGrew et 
al., 2004). Furthermore the fully edited human VGV isoform shows a 40-fold 
decrease in 5-HT potency (Figure 10) and a complete loss of constitutive activity 
of the receptor, which is an indirect measure of G-protein coupling efficiency.  
Niswender et al. (1999) also showed that 5-HT2C receptor editing eliminates 
agonist high affinity binding, and inferred that G-protein coupling is compromised. 
The high affinity state of the receptor is the conformation that occurs after the 
dissociation of GDP and  prior to the association of GTP (R*, Figure 11). GTP 
analogs eliminate the preferential binding of 5-HT to the high affinity state of the 
receptor as illustrated in figure 12a. This effect is lost in 5-HT2C-VGV receptors. 
The curves for 5-HT2C-INI receptors show two binding sites, brought to light by the 
addition of Gpp(NH)p, while only a single low affinity state exists in the cell line 
expressing 5-HT2C-VGV receptors(Figure 12b). 
  
 While the 5-HT2C and 5-HT2B receptors remain largely indistinguishable 
pharmacologically, numerous studies have elucidated the opposing relationship 
of 5-HT2A and 5-HT2C receptors in a variety of physiological responses such as 
locomotion, impulsivity, and dopaminergic modulation despite their 51% amino 
acid homology (Winstanley et al., 2004; Fletcher et al., 2007; Robinson et al., 
5-HT2A Receptor vs. 5-HT2C Receptor 
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2008; Halberstadt et al., 2009). A number of radioligands are available for each 
receptor, two of the more commonly used antagonist ligands are [3H]-ketanserin, 
a 5-HT2A receptor antagonist, and [3H]-mesulergine, a 5-HT2C receptor 
antagonist. Both ligands are often used in membrane binding and 
autoradiographic studies, but conditions must be adjusted to mask binding to the 
other site. [125I]-DOI is an agonist radioligand with relatively equal affinity for both 
receptors and assays using this ligand must be further differentiated using a 
selective antagonist. There are a few truly selective antagonist ligands for the 5-
HT2A receptor, and fewer still for the 5-HT2C receptor (Table 3). To further 
complicate differentiation of 5-HT2A and 5-HT2C receptors, the selectivity of drugs 
may vary from species to species, a complication often ignored. 
 
Specific Aims 
 
 Given the wide variety of processes the 5-HT2C receptor modulates and 
evidence for changes in editing in affective disorders, examining the impact of 5-
HT2C receptor editing in vivo is of great importance. With that goal in mind the 
objectives of my project were to: 
1. Establish conditions for specifically measuring 5-HT2C receptors in mice 
2. Predictably manipulate 5-HT2C receptor mRNA editing in a single mouse strain  
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3. Evaluate in vivo functional consequences of 5-HT2C receptor RNA editing at 
the level of receptor signaling and secondarily using biochemical and behavioral 
measures.
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Figure 11: Agonist Activation of 5-HT2C Receptors 
Different conformations of the 5-HT2C receptor highlighting the R* conformation with both agonist and G-protein bound to 
the receptor. We define this as the high affinity state of the receptor. 
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A B 
Figure 12. 5-HT2C Editing Eliminates Agonist High Affinity Binding 
5-HT affinity for human edited 5-HT2C receptors and modulation by the GTP analogue Gpp(NH)p. Competition binding 
analyses are shown for 5-HT2C-INI (A) and 5-HT2C-VGV (B) receptor cell lines in the presence (closed symbols) and 
absence (open symbols) of 100 µM Gpp(NH)p. Increasing concentrations of 5-HT were incubated with [3H]mesulergine 
(From Niswender et al., 1999) 
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Table 3 
Affinity (Ki nM) of Various 5-HT2 Ligands at Human Receptors 
 
 
 5-HT2A 5-HT2B 5-HT2C 
5-HT2A receptor     
Spiperone 
(antagonist) 1.59 >1,000 884 
M100907  
(antagonist) 0.84 261 99.7 
Ketanserin 
(antagonist) 1.13 911 88.1 
5-HT2B receptor     
5-MeOT(agonist) 392 8.46 52.4 
α-Methyl-5-HT 13 10.1 2.69 
SB204741(antagonist) >10,000 94.9 >2,000 
5-HT2C receptor    
SB242084 
(antagonist) 851 144 0.478 
RS102221 
(antagonist) >1,000 >1,000 2.64 
RO60-0175 
 (agonist) 446 4.29 26.9 
WAY629  
(agonist) >2,000 N/A 56 
5-HT2B/2C receptors    
SB200646 
(antagonist) >5,000 31.6 (rat) 100 
mCPP  
(agonist) 142 30.3 147 
SB221284 
(antagonist) 549 2.45 2.18 
SB206553 
(antagonist) >1,000 5.49 7.59 
MK212 (agonist) >17,000(rat) 616 891 
Non-Selective    
DOI (agonist) 45 20 18.6 
 
Ki values (nM) taken from PDSP database (http://pdsp.med.unc.edu/pdsp.php). 
Values were calculated using competition binding vs. established standard 
antagonist if available; [3H]-Ketanserin for 5-HT2A, [3H]-5HT for 5-HT2B, and [3H]-
Mesulergine for 5-HT2C. All data is from cloned human receptors except where 
noted. * Some ligands have significant affinity for non-serotonin receptors. 
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Chapter II: Ligand Specificity in Mice 
 
Introduction 
 
In order to examine the functional properties of the 5-HT2C receptor in vivo and 
ex vivo, we must first be able to selectively label and activate the receptor. As 
discussed in Chapter I, while there are relatively selective ligands at each human 
receptor, the selectivity of these and most other ligands in mice has been virtually 
unexplored. This is disturbing considering the volume of pharmacological data 
generated using mice. We used competition binding to determine ligand affinities 
at both mouse 5-HT2A and mouse 5-HT2C receptors ex-vivo. Competition binding 
works by using a competing test ligand to compete with a radioligand incubated 
in parallel.  With increasing concentrations of a test ligand, I can generate a 
competition curve that can be used to determine the IC50 and Ki of each test 
ligand.  Determining ligand selectivity in vivo is far more difficult; we attempted to 
do so using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), which has 
been used for a few decades to block and inactivate various receptor binding 
sites including but not limited to:  alpha-adrenergic (Adler et al., 1985; Ribas et 
al., 2001), dopaminergic (Meller et al, 1985; Stanwood et al., 2000) and 
serotonergic (Battaglia et al., 1987; Gozlan et al., 1994; Vinod et al., 2001). The 
irreversible blockade occurs in two steps. The first step consists of EEDQ 
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reacting with a carboxylic group in the receptor protein, forming a mixed 
anhydride corresponding to an activated ester (Figure 16). In the second step, 
this intermediate can react with any nucleophillic group in its vicinity to form an 
irreversible bond (Martel et al., 1969; Meller et al., 1988). Even though it has no 
chemical specificity EEDQ does not affect all receptor types, for example mouse 
5-HT2A receptors are more sensitive to EEDQ inactivation than mouse 5-HT2C 
receptors (my observations), and D2 receptors are more sensitive than D1 
(Cameron and Crocker, 1988). 
 
Materials and Methods 
 
Animals 
 All experiments involving animals were approved by the Institutional 
Animal Care and Use Committee of Vanderbilt University. Naive male Jax® 
129S1 mice, 3 to 6 months of age, were used for all experiments. Mice were 
housed in groups of 3 to 5 in a temperature controlled colony room (ambient 
temperature 22-23°C, 12:12 light: dark cycle).  Food and water were available ad 
libitum, and all testing occurred between 1200 and 1700 during the light phase.  
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Drugs and Radioligands 
SB206553 hydrochloride [3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-
b:4,5-b']di pyrrole-1(2H)-carboxamide hydrochloride] and spiperone hydrochloride 
[8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazas piro[4,5]decan-4-one 
hydrochloride] were purchased from Tocris Bioscience ( Ellisville, MO, USA) and 
dissolved in deionized water. M100907 [α-(2,3-dimethoxyphenyl)-1-(2-(4-
fluorophenylethyl))-4-piperidine methanol] was a gift from Marion Merrill-Dowell 
(Cincinnati, OH) and was dissolved in 0.02% tartaric acid.  All drugs were 
administered subcutaneously (s.c.) at a volume of 10ml/kg. 
 
Radioligand Binding 
 Mice were anesthetized using isoflurane and decapitated. Brains were 
removed, placed in a slicing mold, and sliced coronally rostral to the optic 
chiasm. Tissue anterior to the cut was homogenized in 20ml of ice cold binding 
buffer (50mM Tris base, 10mM MgCl2, 0.1% ascorbic acid, pH 7.4).  
Homogenates were centrifuged at 15,000 x g for 20 min. at 4°C. The resulting 
pellet was re-suspended in fresh binding buffer and incubated at 37°C for 15 
minutes, then centrifuged a second time. The final pellet was re-suspended in 
sufficient binding buffer to yield a protein concentration 0.6 to 1mg/ml. 
Competition binding was performed with 4nM [3H]-mesulergine in the 
presence of increasing concentrations of an unlabeled competitor at 37°C for 60 
min. IC50 values were determined by fitting data to a sigmoidal curve with 
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variable slope using GraphPad Prism® (GraphPad Software, Inc., USA). The 
procedure for 5-HT2A receptor competition binding was identical with the following 
exceptions; binding was carried out in membranes derived from 5-HT2C receptor 
knock-out mice on a C57B6 background and binding sites were labeled with 4nM 
[3H]-ketanserin. IC50 values were converted to Ki using the transformation of 
Cheng-Prusoff (Cheng and Prusoff, 1973).   
  5-HT2C receptor binding assays were run on the same day as the 
membrane preparation to avoid a decrease in signal due to freezing. Assays 
were carried out in triplicate and incubated for 90 min in a 37°C water bath at 
final volume of 600 µl, consisting of 500 µl of membrane suspension (300-500 µg 
protein), 50 µl of radioligand, and 50 µl of antagonist to mask alternative binding 
sites as appropriate. Non-specific binding was determined in the presence of 100 
µM methysergide. Reactions were terminated by the addition of ice-cold Tris 
buffer (50 mM tris base pH 7.4 at 25°C), and membranes were collected by 
vacuum filtration (Brandel harvester) using Whatman GF/B glass fiber filters 
presoaked in 0.3% polyethylenimine. Filters were rinsed 3 times with cold Tris 
buffer, and the bound radioactivity was determined by liquid scintillation 
spectrometry after soaking overnight in scintillation cocktail (Aquasol-2, 
PerkinElmer, Boston, MA USA). Data were analyzed using nonlinear regression 
(GraphPad Prism, Graphpad Inc., USA). Total density for EEDQ assay was 
estimated in each membrane preparation using a single saturating concentration 
of 5nM [3H]-Ketanserin. 
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EEDQ Receptor Inactivation Protection Assay 
SB206553 (2, 3, 4, and 6mg/kg, 10ml/kg) and M100907 (0.25mg/kg, 
10ml/kg) were administered subcutaneously (s.c.) 30 minutes prior to EEDQ. 
EEDQ was dissolved in 20% ETOH and administered s.c. at 10mg/kg and 
10ml/kg. Animals were left in home cages and sacrificed 24 hours later (Figure 
17). Single concentration binding assays were conducted as previously 
described.  
 
Results and Discussion 
 
Competition Binding 
Ki values were determined for spiperone, M100907, and SB206553 at 
both the 5-HT2A and 5-HT2C receptors (Table 4). Unlike in human and rat derived 
membranes, M100907 was not as selective for 5-HT2A  receptor in mouse tissue. 
Based on the competition curves it became obvious that we could not eliminate 
all [3H]-ketanserin binding to 5-HT2A receptor using M100907, without interfering 
with the 5-HT2C receptor binding signal (Figure 13). We turned to spiperone, 
which while toxic in vivo, served our needs in vitro. 1µM Spiperone added to our 
binding buffer blocks all [3H]-ketanserin 5-HT2A receptor binding sites, while 
eliminating no [3H]-mesulergine binding to 5-HT2C receptors (Figure 14). 10µM 
SB206553 allowed us to eliminate [3H]-mesulergine binding to 5-HT2C receptors 
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without diminishing [3H]-ketanserin binding to 5-HT2A receptors (Figure 15). 
Masking antagonists as determined in competition binding were added to buffer 
solution for saturation binding experiments: 1 µM spiperone to block 5-HT2A 
receptor; 10 µM SB206553 to block the 5-HT2C receptor. We used these ligand 
concentrations, as appropriate, in our binding buffers in all subsequent binding 
experiments.   
  
EEDQ Inactivation Protection Assay 
 Although 10 mg/kg EEDQ very effectively inactivated 77% of 5-HT2A 
receptors (Figure 18), it was ineffective at the 5-HT2C receptor (Figure 19). As a 
result, while we could not determine the in vivo selectivity of M100907, we have 
clearly established 3mg/kg of SB206553 as selective for 5-HT2C receptor over 5-
HT2A receptors in JAX 129S1 mice. Doses of 3 and 4 mg/kg of SB206553 failed 
to protect 5-HT2A receptors from EEDQ inactivation (Figure 20). 
 
Predictably Manipulating 5-HT2C receptor mRNA editing 
 We initially attempted to manipulate 5-HT2C mRNA editing using the SSRI 
fluoxetine in the same manner as Englander et al. (2005), but were unsuccessful 
(data not shown). Fortunately we were able to make use of transgenic mice 
created by the Emeson group at Vanderbilt University that solely express the fully 
edited 5-HT2C-VGV isoform of the receptor. 
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Ligand  
Species 
Mouse Human Rat 
5-HT2A 5-HT2C 5-HT2A 5-HT2C 5-HT2A 5-HT2C 
M100907  2.15±0.42 93±4.35 0.84 99.72 1.92 104.07 
Spiperone  3.37±0.31 3676 ±340 1.59 884 1.07 1700 
SB206553  15000±5000 139.5±19.2 1659 7.59 N/A N/A 
Table 4. 5-HT2 Ligand Affinities Across Species 
Ki (± S.E.M) for M100907, Spiperone, and SB206553 in mouse, human, and rat tissue. Ki were determined using 
radioligand competition binding assays. Ki data for human and rat are courtesy PDSP Ki database 
(http://pdsp.med.unc.edu/indexR.html). Each mouse data point represents the average of 4 experiments performed in 
triplicate.  
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Figure 13. M100907 Competition Binding 
Representative plots of increasing concentrations of M10097 versus constant concentrations of [3H]-Mesulergine and 
[3H]-Ketanserin. 
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Figure 14. Spiperone Competition Binding 
Representative plots of increasing concentrations of Spiperone versus constant concentrations of [3H]-Mesulergine and 
[3H]-Ketanserin. 
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Figure 15. SB206553 Competition Binding 
Representative plots of increasing concentrations of SB206553 versus constant concentrations of [3H]-Mesulergine and 
[3H]-Ketanserin. 
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Figure 16. EEDQ Irreversibly Inactivates 5-HT2A Receptors 
EEDQ reacts with a carboxyl group important for receptor activation, which is most likely located at or near the active 
binding site of the 5-HT2A receptor. This reaction produces a highly reactive mixed carbonic anhydride which then reacts 
with any nucleophilic group to form an irreversible bond. (See Chang et al. (1970) for chemical details). 
EEDQ 
Carbonic Anhydride 
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Antagonist Injection 
(M100907 or SB206553) 
30 Minutes 
EEDQ Injection 
24 Hours 
Single Concentration  
Radioligand Binding 
Figure 17. EEDQ Protection Assay Methods 
Mice were injected with either the 5-HT2A antagonist M100907 (0.25mg/kg) or the 5-HT2C antagonist/inverse agonist 
SB206553 (3mg/kg). 30 minutes later animals were injected with 10mg/kg EEDQ. 24 hours after EEDQ injections 
animals were sacrifice and single concentration antagonist radioligand binding was assayed the same day.  
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Figure 18. EEDQ Dose Response at 5-HT2A Receptors 
[3H]-Ketanserin binding 24 hours after 1, 3, and 10 mg/kg EEDQ administration (S.C.). 10mg/kg EEDQ eliminated 77% of 
control [3H]-ketanserin binding. * F(3,8) = 10.93 p<0.01. 
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Figure 19. EEDQ is Ineffective at 5-HT2C Receptors 
10 mg/kg was ineffective in reducing [3H]-mesulergine binding in mouse derived membranes. 
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Figure 20. SB206553 does not occupy 5-HT2A Receptors 
[3H]-ketanserin binding 24 hours after EEDQ and 30 minute pretreatment with M100907 (0.25mg/kg) or SB206553 
(3mg/kg) followed by EEDQ administration. M100907 completely blocks the effect of EEDQ, while SB206553 has no 
effect on EEDQ inactivation of 5-HT2A receptors. 
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Chapter III: In Vivo Function Of the 5-HT2C-VGV Receptor 
 
 Introduction 
  
 The serotonin 2C (5HT2C) receptor modulates a number of 
neurophysiological functions including appetite, mood, sexual behavior, and 
locomotion (Buhot, 1997; Giorgetti and Tecott, 2004; Millan, 2005; Olivier et al., 
1998), and is implicated in the etiology of psychiatric disorders such as 
depression, anxiety, anorexia-nervosa,  and obsessive-compulsive disorder 
(Berg et al., 2008b; Delgado and Moreno, 1998; Flaisher-Grinberg et al., 2008; 
Griebel, 1995).  Consequently, the 5HT2C receptor has received considerable 
attention as a target for pharmacological treatment of these conditions (Halford et 
al., 2007; Meltzer et al., 2003; Millan, 2005; Morabito and Emeson, 2009; Serretti 
et al., 2004).   
 A distinctive feature of the G-protein coupled 5HT2C receptor is its ability to 
be modified post-transcriptionally by RNA editing (Burns et al., 1997).  RNA 
editing is an enzymatic process that converts adenosine to inosine at 5 
nucleotide positions in the 5th exon of the 5HT2C receptor RNA transcript, 
encoding the second intracellular loop, a region important for G-protein coupling.  
Selective RNA editing can generate up to 24 protein isoforms of the 5HT2C 
receptor potentially adding immense diversity to the function of the receptor in 
vivo.   
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 In vitro studies in transfected cells expressing a single isoform show that 
differentially edited 5HT2C receptor isoforms have unique signaling features, with 
increased editing generally leading to decreased function.   For example, the 
edited isoform valine-serine-valine (at amino acid positions 157, 159, 161 in 
humans) has four-fold reduced constitutive activity and four- to five-fold reduced 
serotonin potency to activate phospholipase C (PLC) relative to the non-edited 
isoleucine-asparagine-isoleucine isoform (INI) (Fitzgerald et al., 1999; Herrick-
Davis et al., 1999; Niswender et al., 1999). The function of the fully edited valine-
glycine-valine (VGV) isoform is reduced even further.  
 Since the first report identifying and characterizing RNA editing of the 
5HT2C receptor transcripts in rat brain (Burns et al., 1997), many laboratories 
have observed a large repertoire of differentially edited 5HT2C receptor RNA 
isoforms uniquely distributed in the mammalian brain.  Recent studies using 
animal models suggest that RNA editing of the 5HT2C receptor is a dynamic 
process.  For example, chronic stress increases RNA editing of the 5HT2C 
receptor in both mice (Englander et al., 2005) and rats (Iwamoto et al., 2005).  
Variation in 5HT2C receptor RNA editing has also been implicated in a variety of 
neuropsychiatric disorders, with the most reproducible finding being an increase 
in RNA editing in brains of suicide victims (Dracheva et al., 2008a; Dracheva et 
al., 2008b; Gurevich et al., 2002; Niswender et al., 2001).   
 Despite these findings, defining the in vivo functional consequences of 
5HT2C receptor RNA editing has been limited due to the technical constraints 
presented by the immense diversity of receptor isoforms in brain.  Here we take 
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advantage of mutant mice solely expressing a single isoform, the fully-edited or 
non-edited 5HT2C receptor (Canal et al., 2009; Kawahara et al., 2008), to 
characterize for the first time the signal transduction consequences of RNA 
editing of the 5HT2C receptor in vivo.  We show that G-protein coupling to the fully 
edited 5HT2C-VGV receptor in brain is nearly abolished.  However, the functional 
consequences at the level of behavior in mice solely expressing the 5HT2C-VGV 
receptor do not reproduce these signaling alterations, because of a marked 
increase in 5HT2C receptor binding site density. 
 
Materials and Methods 
 
Animals  
 All experiments involving animals were approved by the Institutional 
Animal Care and Use Committee of Vanderbilt University. Naive adult mice, 3 to 
6 months of age, were used for all experiments. Mice were housed in groups of 2 
to 5 in a temperature controlled, colony room (ambient temperature 22-23°C, 
12:12 light: dark cycle).  Food and water were available ad libitum, and all testing 
occurred between 1200 and 1700 during the light phase. Unless otherwise 
indicated, male mice were used. 
VGV mutant mice were generated by the laboratory of Dr. Ronald 
Emeson, Vanderbilt University by introducing guanosine residues instead of 
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adenosine at all five edited sites (Morabito et al., 2007), and were maintained on 
a  mixed JAX® 129S1/Taconic® 129S6 background.   Four genotypes of mice 
were used in the experiments examining functional characteristics of the in vivo 
expressed 5HT2C-VGV receptor: wild-type males and females (WT), heterozygous 
females (VGV/X), and hemizygous (the 5HT2C receptor is X-linked) males 
(VGV/Y), expressing solely the VGV isoform.   Heterozygous female VGV/X 
mice, with approximately one-half of the RNA isoforms encoding the fully edited 
5HT2C-VGV receptor, were used to assess the possible contribution of gene 
dosing. Using the method of pyrosequencing (Canal et al., 2009), we verified that 
VGV/X females had VGV as their major isoform; VGV/X females (N=4, average 
of 60 sequences per mouse) had an average of 62% of RNA isoforms that 
translate to VGV. Control mice (N=4, average of 60 sequences per mouse) had 
less than 1% VGV isoforms. We also verified that the increase in the percentage 
of the VGV isoform in VGV/X did not alter the remaining distribution of isoforms 
(data not shown). 
INI mutant mice were created by introducing multiple mutations into intron 
5 to disrupt base-pairing with exon 5 and prevent RNA editing  and were 
maintained on a 129S6 background.   Two genotypes of mice were used in the 
experiments examining receptor density characteristics of the in vivo expressed 
5HT2C-INI receptor: WT males and hemizygous mutant male (INI/Y) littermates, 
solely expressing the INI isoform. 
The genotypes of all mice were determined by PCR analysis of genomic 
DNA from tail samples using the RED Extract-N-Amp tissue PCR kit (Sigma, St. 
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Louis, MO, USA), with the following primers: 5' GGG CAA ATA TTC TGA AAA 
GAT GTT 3’ (reverse) and 5' AAT ATC AAT AGG TAA TTA TAC C 3’ (forward).  
 
Drugs and Radioligands 
MK212 hydrochloride [6-Chloro-2-(1-piperazinyl) pyrazine hydrochloride], 
purchased from Tocris Bioscience (Ellisville, MO, USA), was dissolved in 
deionized water, and injected subcutaneously (s.c.) at a volume of 10 ml/kg.  [N6-
methyl-3H]-Mesulergine ([3H]-mesulergine) was purchased from GE 
Healthcare/Amersham (Buckinghamshire, UK). (±)-1-(2,5,-dimethoxy-4-
[125I]iodophenyl)-2-aminopropane ([125I]-DOI) was purchased from Perkin Elmer 
(Boston, MA, USA).  Spiperone and methysergide were purchased from Sigma-
Aldrich (St. Louis, MO, USA); SB204741 was purchased from Tocris.  
 
GTP-Sensitive High-Affinity Agonist Binding In Membranes  
Agonists, such as DOI, bind preferentially to 5HT2C receptors existing in a 
high-affinity state,  a receptor conformation that is coupled to G-protein.  In vitro, 
5HT2C-VGV receptors show no basal coupling to G-proteins (Herrick-Davis et al., 
1999; Niswender et al., 1999).  Mice were briefly anesthetized using isoflurane 
and decapitated. Unless otherwise indicated, brains were removed, placed in a 
slicing mold, and sliced coronally at the level of the optic chiasm. Tissue anterior 
to the cut, defined here as frontal cortex, was assayed.  Tissue was 
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homogenized in 20 ml of ice cold binding buffer (50mM Tris, 10mM MgCl2, 0.1% 
ascorbic acid, pH 7.4).  Homogenates were centrifuged at 15,000 x g for 20 min. 
at 4°C.   Supernatant was decanted, and the pellet was resuspended in fresh 
binding buffer and incubated at 37°C for 15 minutes to dissociate endogenous 
ligand from receptors.  After a second centrifugation, supernatant was decanted, 
and the pellet re-suspended in fresh, cold binding buffer.  Binding assays were 
performed on the same day as the membrane preparation to avoid a decrease in 
signal due to freezing.   
[125I]-DOI saturation binding was performed on membranes from VGV/Y 
and WT mice to test potential differences in the proportion of receptors in the 
agonist high-affinity conformation. Assays were carried out in triplicate and 
incubated for 90 min in a  37°C water bath  at final volume of 600 µl, consisting of 
500 µl of membrane suspension, 1 µM spiperone to mask 5-HT2A and 5-HT7 
binding sites and increasing concentrations of [125I]-DOI.  Nonspecific binding 
was determined in the presence of 100 µM methysergide.   Data were analyzed 
using nonlinear regression (GraphPad Prism 5.02, Graphpad Inc., USA). In a 
separate experiment, GTP sensitivity was evaluated using a single concentration 
of [125I]-DOI (1 nM) in the absence and presence of 200 µM guanylyl-5 -
imidodiphosphate (Gpp(NH)p), a nonhydrolyzable analog of GTP that prevents 
G-protein coupling.  Total density was estimated in each membrane preparation 
using a single saturating concentration of 30nM [3H]-mesulergine.   
   Samples were incubated for 90 min in a 37°C water bath, and the 
reactions were terminated by the addition of ice-cold 50 mM Tris buffer.  
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Membranes were collected by vacuum filtration (Brandel harvester) using 
Whatman GF/B glass fiber filters presoaked in 0.3% polyethyleneimine.  Filters 
were rinsed 3 times with cold Tris buffer, and the bound radioactivity was 
determined by liquid scintillation spectrometry after soaking filters overnight in 
scintillation cocktail (Aquasol-2, PerkinElmer, Boston, MA USA). 
  
[125I]-DOI and [3H]-Mesulergine Autoradiography 
Mice were anesthetized with isoflurane inhalation, followed by 
decapitation.  Brains were quickly removed and frozen in 2-methylbutane on dry 
ice, dried briefly with a Kimwipe (Kimberly-Clark, Roswell, GA, USA), wrapped in 
aluminum foil and stored at -80˚C.  Brains were brought to -20˚C in a cryostat 
(Leica, Wetzlar, Germany), sectioned at 20 μm and thaw mounted onto 
Superfrost glass slides (Fisher, USA), then stored at -80˚C until the 
autoradiographic assay.   
For [125I]-DOI autoradiography, slides were thawed at room temperature 
for 30 min, followed by incubation for 30 min in assay buffer containing 50 mM 
Tris, 5 mM MgSO4, 4 mM CaCl2 and 0.5 mM EDTA.  Slides were then transferred 
to assay buffer that contained one of four drug treatments: 1) 0.14 nM [125I]-DOI 
to label 5HT2A and 5HT2C receptors; 2) 0.14 nM [125I]-DOI plus 1 μM spiperone to 
identify the 5HT2C receptor; 3) 0.14 nM [125I]-DOI plus 100 μM GTPγS to identify 
GTP-sensitive high affinity [125I]- DOI binding (Appel et al., 1990); 4) 0.14 nM 
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[125I]-DOI plus 30 μM methysergide to define non-specific binding.  Slides were 
incubated with radioligand at room temperature for 60 min.   
[3H]-mesulergine autoradiography procedures were identical to [125I]-DOI 
autoradiography with the following exceptions.  The assay buffer for [3H]-
mesulergine was 50 mM Tris, 10 mM MgCl2, and 0.1 mM EDTA.  The binding 
conditions were: 1) 3 nM [3H]-mesulergine; 2) 3 nM [3H]-mesulergine plus 1 μM 
spiperone; 3)  3 nM [3H]-mesulergine plus 30 μM methysergide to define non-
specific binding.  Slides were incubated for 120 min at room temperature. 
Slides were washed 4x10 min in ice-cold 50 mM Tris buffer, pH 7.4 and 
dried with a steady stream of dehumidified air. After air drying for an additional 90 
min, slides were placed in autoradiography cassettes and exposed to Kodak 
Biomax MR film (Carestream Health, Inc., USA) for 24 to 48 hours for [125I]-DOI 
or 6 to 8 weeks for 3H-mesulergine prior to developing (shorter exposures were 
required for brain sections from VGV/Y mice to accommodate an increased 
density of 5HT2C receptors).  Film was scanned (CanoScan 4400F, Canon, USA) 
onto a PC, and images were analyzed with Image J software (Abramoff et al., 
2004).  The average of the minimum gray value (darkest area) from three brain 
slices containing brain area of interest was converted to μCi/g protein using 14C 
standards (ARC, Inc., St. Louis, MO) for statistical comparisons of specific [125I]-
DOI binding, and 3H standards for statistical comparisons of specific [3H]-
mesulergine.  Data were compared using 2-tailed unpaired t-tests. 
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5HT2C  Receptor Agonist Impact On Locomotor Activity In VGV/Y And VGV/X  
 5HT2C receptor agonists induce hypolocomotion in a 5HT2C- and dose-
dependent manner (Fone et al., 1998; Gleason et al., 2001; Stiedl et al., 2007).  
Dose-response studies were conducted to assess the locomotor effects of 
MK212, a selective 5HT2C receptor agonist (Fletcher et al., 2009), in WT, VGV/Y 
and female VGV/X. Locomotor activity was measured in Plexiglas activity 
chambers (11x11x11in; LxWxH; Med Associates St. Albans, Vermont), equipped 
with 16 infrared beams to monitor and record beam breaks in the x-y-z 
coordinates.  VGV/Y and VGV/X mice were tested with saline and MK212 at 
doses of 0.01, 0.03, 0.1, 0.3 and 1.0 mg/kg. Twenty min after s.c.injection, 
individual mice were placed inside the activity chamber and distance traveled 
was recorded for 10 minutes using Activity Monitor software version 5 (Med 
Associates, St. Albans, Vermont, USA).  Dose-response data were analyzed by 
two-way ANOVA for independent groups. 
 
Biogenic amine levels 
DA and 5-HT levels were quantified by previously described high-
performance liquid chromatography (HPLC) electrochemical detection methods 
(Vanderbilt Neurochemistry Core).  Animals were anesthetized with isoflurane 
and rapidly decapitated after cervical dislocation. Brains were removed and 
placed in a chilled stainless steel mold for dissection – the tissue slice 1.7 to 3.6 
relative to bregma is referred to as cortex; striatum represents slice 1.70 to -0.82  
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relative to bregma with the cortex removed by freehand dissection.  Tissue was 
frozen rapidly on dry ice and stored at -80°C until assay. Thawed samples were 
homogenized in 250µl acetonitrile and centrifuged at 13,000x g for 30 minutes. 
The acetonitrile fraction was transferred to a clean tube, washed twice with 125 
µl heptane and then evaporated using a stream of nitrogen.  The sample was 
suspended in 75µl of the HPLC mobile phase (37.5 mmole H3PO4, pH 8.5) and 
50µl was injected into the equilibrated HPLC. Dopamine turnover was measured 
by the ratio DOPAC/DA and serotonin turnover was measured by the ratio 
5HIAA/5HT.  Each measure was predicted by a mixed ANOVA model that 
incorporated between-subject fixed effects for genotype (VGV or WT) and drug 
(saline or SB206553), a within-subject fixed effect for brain area (cortex or 
striatum), and a random effect to account for repeated measures in each mouse. 
 
[3H]-Mesulergine Saturation Binding In Membranes  
 The procedures for [3H]-mesulergine saturation binding were essentially 
identical to [125I]-DOI binding in membranes. Membrane homogenates, binding 
buffer, spiperone at a final concentration of 1µM for VGV membranes and 100 
nM for INI membranes, and increasing concentrations of [3H]-mesulergine up to 
36 nM were added. Non-specific binding was determined in the presence of 100 
µM methysergide.  Frontal cortex was used for studies with VGV/Y and WT 
littermates.  Whole brain minus cerebellum was used for studies with INI/Y and 
WT littermates. 
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Results 
 
5HT2C-VGV Receptors In Brain Exhibit Undetectable Agonist High-Affinity Binding  
In saturation binding assays of membranes from WT littermates, the 
binding of the radiolabeled agonist [125I]-DOI was best fit by a two-site equation, 
as illustrated in the Scatchard plot (Figure 21).  Approximately 10% of the binding 
sites were in a high affinity state (Kd=0.51nM); the density of the low affinity site 
(137 fmol/mg protein) was consistent with that found in [3H]-mesulergine binding 
(see below).  In contrast, [125I]-DOI binding in membranes from VGV/Y mice was 
best fit by a one-site equation, as illustrated in the Scatchard plot (Figure 22) with 
a Kd (29nM) that was consistent with the Kd of the low affinity site in WT mice 
(20nM). The extremely high density of binding sites in VGV/Y mice was 
confirmed in [3H]-mesulergine binding experiments (see below). 
    To corroborate the finding of decreased high-affinity binding sites in 
brains of VGV/Y mice and to estimate the percentage of G-protein coupled 
receptors, the binding of a single concentration of [125I]-DOI binding was 
determined in the absence and presence of Gpp(NH)p to uncouple the receptor-
G-protein complex.  Approximately four percent (3.6 ±0.42; N=4) of the specific 
[125I]-DOI binding to 5HT2C receptors was Gpp(NH)p sensitive in membranes from 
WT mice (Figure 24).  However, there was essentially no Gpp(NH)p-sensitive 
5HT2C receptor binding in brains of VGV/Y mice (Figure 23). 
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Figure 21. Agonist High Affinity Binding: Membranes From WT Mice. 
Representative saturation plots of specific [125I]-DOI binding are shown for 
membranes from WT mice. Increasing concentrations of [125I]-DOI are plotted 
on the x-axis and density (fmol/mg protein) is plotted on the y-axis. Data were 
tested for best fit to one- or two-site models (GraphPad Prism 5.02).  Insets 
show Scatchard transformation of the saturation binding data, bound/free (y-
axis) versus bound (x-axis).  Scatchard plots illustrate the presence of a high-
affinity agonist binding site in WT mice  
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Figure 22. Agonist High Affinity Binding: Membranes From VGV/Y Mice. 
Representative saturation plots of specific [125I]-DOI binding are shown for 
membranes VGV/Y mice . Increasing concentrations of [125I]-DOI are plotted on 
the x-axis and density (fmol/mg protein) is plotted on the y-axis. Data were 
tested for best fit to one- or two-site models (GraphPad Prism 5.02).  Insets 
show Scatchard transformation of the saturation binding data, bound/free (y-
axis) versus bound (x-axis).  Scatchard plots illustrate the absence of high-
affinity agonist binding sites in VGV/Y mice  
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Figure 23. GTP Sensitive Agonist Binding 
Gpp(NH)p (200µM) was added to assay buffer containing 1nM [125I]-DOI to eliminate high affinity binding; the [125I]-DOI 
binding in the absence and presence of Gpp(NH)p is plotted.  Membranes from VGV/Y show no detectable GTP-
sensitive [125I]-DOI binding to 5HT2C receptors.  A significant effect of genotype was observed (F (1,43)=54.66, p<.0001) 
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Figure 24. GTP Sensitive Antagonist Binding 
Gpp(NH)p (200µM) was added to assay buffer containing 1nM [125I]-DOI to eliminate high affinity binding; the percentage 
of binding eliminated is plotted. Total receptor density in each preparation (N=4) was estimated using a saturating 
concentration of [3H]-mesulergine.  The values plotted are percentage of total receptor density eliminated by Gpp(NH)p.  
Membranes from VGV/Y show no detectable GTP-sensitive [125I]-DOI binding to 5HT2C receptors.  *Denotes significantly 
different from WT.  
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5HT2C-VGV  Receptors in Brain Exhibit Low Agonist High-Affinity Binding 
 [125I]-DOI binding to 5HT2C receptors was clearly visible in the choroid 
plexus in brain slices from WT and VGV/Y; thus the choroid plexus was used for 
analysis of GTP sensitivity of 5HT2C receptor binding.  As illustrated in Figure 25, 
the addition of GTPγS to WT sections incubated with [125I]-DOI decreased 
specific binding in choroid plexus (45.7 ± 6.52 percent decrease; N=5; P < 0.05).  
However, GTPγS did not significantly alter [125I]-DOI binding in choroid plexus of  
brains from VGV/Y mice (5.5 ± 3.89 percent decrease; N=6; P = 0.15), 
confirming greatly reduced agonist high-affinity binding at 5HT2C-VGV receptors.  
 
VGV/Y and VGV/X Mice Have Increased Sensitivity to 5HT2C Receptor Agonist 
Injection of the 5HT2C selective agonist, MK212, dose-dependently 
decreased total distance traveled in all genotypes, yet the potency of MK212 was 
greater in mutant mice relative to their respective WT littermates.  For WT, 
female VGV/X and VGV/Y mice (Figure 26), a 2-way ANOVA revealed main 
effects of dose (F5, 135 = 31.77, p < 0.0001) and genotype (F2, 135 = 42.46, p < 
0.0001). The potency of MK212 was 10-fold higher in VGV/Y and VGV/X mice 
relative to WT’s (Figure 26; N=10;). For example, 0.1 mg/kg MK212 essentially 
eliminated locomotor activity in VGV/Y mice (posthoc Fisher least significant 
difference (LSD) test, saline vs. 0.1 mg/kg, P < 0.001), whereas this dose did not 
reduce locomotor activity in WT mice (posthoc Fisher LSD test, saline vs. 0.1 
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mg/kg, P = 0.58). There were no gender differences in the motor effects of 
MK212 in WT mice (data not shown). 
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Figure 25. Agonist High Affinity Binding: Autoradiography  
Representative [125I]-DOI autoradiography of brain sections from WT and VGV/Y 
mice.  Sections incubated in: a. 0.14 nM [125I]-DOI; b. a plus 1 µM spiperone; c. 
a plus 100 µM GTPγS; d. a plus 30 µM methysergide. The addition of GTPγS 
reduced binding in choroid plexus of sections from WT, but not VGV/Y, 
demonstrating decreased high affinity agonist binding at 5-HT2C-VGV receptors. 
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Figure 26. MK212 Dose-Dependent Induction Of Hypolocomotion 
Locomotor activity of WT, VGV/X, and VGV/Y mice after single subcutaneous 
injection of saline or MK212 (0.01, 0.03, 0.1, 0.3 or 1.0 mg/kg).  *Denotes 
significantly different from saline within group.  #Denotes significantly different 
from WT.  
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VGV/Y Mice Show Massive Increases in 5HT2C Receptor Density 
[3H]-mesulergine saturation binding was performed to determine the 
maximum density of 5HT2C receptor binding sites in brains of WT, VGV/Y and 
VGV/X mice (Figure 27) and in WT and INI/Y mice (Figure 28).   All plots were 
best fit by a single site equation.  The density of 5HT2C receptors in the frontal 
cortex was increased by 25-fold in VGV/Y mice relative to WT mice (Bmax = 
163.3 ± 5.92 fmol/mg protein in WT vs. 4266 ± 259.9 in VGV/Y; N=4). 
Heterozygous VGV/X mice displayed an approximately 10-fold increase in the 
density of [3H]-mesulergine binding sites (Bmax = 1754 ± 148.7 fmol/mg protein), 
which was intermediate to that observed for WT and VGV/Y mice (Figure 27).  
Conversely, the density of 5HT2C receptors in the brain was decreased by 30% in 
INI/Y mice relative to WT mice (Figure 28; Bmax = 66.94 ± 11.22 fmol/mg protein 
in WT versus 47.31 ± 8.43 INI/Y; N= 5).  The differences in 5HT2C receptor 
density between WT littermates of VGV/Y and INI/Y mice (Figure 27 compared to 
Figure 28) was likely due to differences in brain areas analyzed, i.e. for studies 
with VGV/Y mice, frontal cortex was used, whereas whole brain minus 
cerebellum was used for studies with INI/Y mice. These alterations in receptor 
density (marked increase in VGV/Y mice and decrease in INI/Y mice) were 
confirmed by 3H-mesulergine autoradiography (Clinton Canal, personal 
communication). 
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Figure 27. 5HT2C Receptor Density in VGV/Y and VGV/X Mice 
Representative saturation plots of specific [3H]-mesulergine binding are shown 
for (A) membranes from VGV/X (HET) and VGV/Y mice or (B) membranes 
derived from WT mice. Increasing concentrations of [3H]-mesulergine are 
plotted on the x-axis and density (fmol/mg protein) on the y-axis.   
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Figure 28. 5HT2C Receptor Density in INI MIce 
Representative saturation plots of specific [3H]-mesulergine binding are shown 
for  membranes derived from INI/Y and WT mice. Increasing concentrations of 
[3H]-mesulergine are plotted on the x-axis \and density (fmol/mg protein) on the 
y-axis.  VGV/Y mice had the greatest density, whereas INI/Y mice had the 
lowest density of 5HT2C receptors  
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VGV/Y Mice Show Large Increases in 5HT2C Receptor Autoradiography 
  Similar to results of saturation binding experiments, [3H]-mesulergine 
autoradiographs showed tremendous increases in 5HT2C receptor density in 
VGV/Y mice (Figure 29, WT specific binding versus VGV/Y specific binding in all 
regions examined, P’s < 0.05, e.g. 89 percent increase in nucleus accumbens of 
VGV/Y mice relative to nucleus accumbens of WT; N = 5 WT, N=6 VGV/Y).  
Conversely, 5HT2C receptor density is decreased in INI/Y mice (Figure 30, WT 
specific binding versus INI/Y specific binding, P < 0.05, e.g. 39 percent decrease 
in INI/Y choroid plexus relative to WT choroid plexus; N = 6 WT, 5 INI/Y).  
Addition of 300 nM SB204741 did not alter [3H]-mesulergine binding in WT, 
VGV/Y or INI/Y brain sections, suggesting 5HT2B receptors did not contribute 
significantly to [3H]-mesulergine binding (data not shown). There was a 
widespread increase in 5HT2C receptor binding in thalamus, amygdala, posterior 
cingulate cortex, piriform cortex (Figure 31) and nucleus accumbens as well as 
other olfactory structures (data not shown) in VGV/Y brains compared to WT.  
Decreases in 5HT2C receptor binding in INI/Y brains were seen in the same brain 
structures (Figure 31).  A visual comparison of  3H-mesulergine (plus spiperone) 
binding shows a similar distribution of the 5HT2C receptor in brains of WT and 
VGV/Y mice, suggesting that the overexpression  in the mutant mice does not 
reflect an aberrant distribution of the 5HT2C receptor.  
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Figure  29: VGV/Y [3H]-Mesulergine Autoradiography 
Representative [3H]-mesulergine autoradiography of brain sections from WT 
and VGV/Y mice.  1. Sections incubated in 3 nM [3H]-mesulergine; 2. plus 1 μM 
spiperone; 3. plus 30 μM methysergide  
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Figure 30: INI/Y [3H]-Mesulergine Autoradiography 
Representative [3H]-mesulergine autoradiography of brain sections from WT 
and INI/Y mice.  1. Sections incubated in 3 nM [3H]-mesulergine; 2. plus 1 μM 
spiperone; 3. plus 30 μM methysergide.  These data are courtesy of Dr. Clinton 
Canal. 
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Figure 31: Regional 5-HT2C Receptor Density  
  
[3H]-mesulergine autoradiographs of brain sections displaying 5HT2C receptors 
in WT, INI/Y, and VGV/Y mice.   Increases in 5HT2C receptor expression in 
VGV/Y mice are observed in several brain structures.  Decreases in 5HT2C 
receptor expression in INI/Y mice are shown in the same structures.  
Abbreviations: CP, choroid plexus; PV, paraventricular thalamic nucleus; Pir, 
piriform cortex; Am, amygdala; PCC, posterior cingulate cortex. These data are 
courtesy of Dr. Clinton Canal 
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Biogenic amine levels 
 Given that the 5-HT2C receptor has been reported to exert an 
inhibitory influence on DA release, we investigated if DA turnover was decreased 
in VGV mice and further we assessed whether the inverse agonist, SB206553, 
differentially altered DA turnover in VGV/Y mice as a secondary measure of 
receptor function.  Twenty minutes after treatment with saline or 3 mg/kg of 
SB206553, biogenic amine levels were determined in striatum and cortex of VGV 
and wild-type male mice (Table 5). Dopamine turnover was measured by the 
ratio of DOPAC/DA and serotonin turnover was measured by the ratio 
5HIAA/5HT. Although basal DA turnover was altered in VGV mice, the effect 
was restricted to cortex. After saline injection, the cortex of VGV mice showed 
reduced dopamine turnover (p = 0.039 for DOPAC/DA, least-squared difference 
post-hoc tests, (Figure 32a), which is consistent with literature implicating a 5-
HT2C receptor inhibitory influence on DA release (De Deurwaerdere et al., 2004). 
 A more striking dopamine phenotype occurred in both cortex and striatum 
following SB206553 challenge. Significant genotype by drug interactions were 
observed for the ratio DOPAC/DA (F(1,16)=20.39, p = 0.004) and for 5HIAA/5HT  
(F(1,16)=19.42, p = 0.0004). Similar profiles of the marginal means were 
observed in each model, where VGV mice showed increased turnover, whereas 
WT mice did not (Figure 32a & 32b).  
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TABLE 5. Biogenic Amine: Levels in frontal cortex and striatum after saline and SB206553 administration. 
Frontal Cortex 
Amine/metabolite DOPAC Dopamine 5-HIAA 5-HT HVA 
Genotype WT VGV WT VGV WT VGV WT VGV WT VGV 
Saline 7.1±1.8 10.2±1.8 31.5±10.4 68.2±11.4* 10.4±0.88 13.6±1.7 25.9±1.2 30.8±2.2 6.7±1.6 11.2±1.8 
SB206553 6.6±0.8 15.6±1.7 28.9±6.7 34.2±6.3 9.1±0.7 16.0±0.8 24.5±2.4 20.0±0.9 6.0±0.7 13.9±1.3 
 
 Striatum 
Amine/Metabolite DOPAC Dopamine 5-HIAA 5-HT HVA 
Genotype WT VGV WT VGV WT VGV WT VGV WT VGV 
Saline 15.3±1.3 11.8±0.9 111.9±5.6 116.6±7.5 19.4±3.1 16.9±1.8 26.6±1.6 24.8±1.4 17.1±1.2 27.5±1.5 
SB206553 14.39±1.4 24.1±1.0 110.8±10.7 95.0±15.1 18.9±0.7 26.2±1.1 25.9±1.8 25.4±0.6 16.2±1.3 16.1±1.1 
The results are presented as means ± SEM (n=5). * significantly different from WT, p<0.01. Data were analyzed with anovas 
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Figure 32. SB206553 increases DA and 5-HT Turnover in VGV mice 
(A) Dopamine turnover (DOPAC/DA) following administration of saline or 
SB206553(3mg/kg) in WT (▲) and VGV (●) mice; cortex (left), striatum (right). 
(B) Serotonin turnover (5HIAA/5HT) after the same conditions. 
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  Discussion 
 
5HT2C receptor RNA transcripts undergo five adenosine to inosine RNA 
editing events, resulting in the generation of distinct amino acids in the second 
intracellular loop of the protein, a region critical for G-protein coupling 
(Ballesteros et al., 1998; Gaborik et al., 2003; Moro et al., 1993). Combinations of 
the five edited nucleotides predict 24 different protein isoforms (Burns et al., 
1997);  many isoforms display altered signaling properties in transfection 
experiments in cell lines. The fully-edited VGV isoform, where all five sites are 
edited, shows the most dramatic decrease in agonist potency, as well as 
silencing of receptor constitutive activity and elimination of high-affinity, 
Gpp(NH)p sensitive agonist binding (Niswender et al., 1999).  The current set of 
experiments takes advantage of genetically modified mice solely expressing the 
VGV isoform  to show for the first time, in brain, that RNA editing of the 5HT2C 
receptor alters the proximal event in cell signaling, receptor-G-protein coupling.  
Several techniques were used to highlight the in vivo properties of the 
5HT2C-VGV receptor including [3H]-mesulergine saturation binding, [3H]-
mesulergine autoradiography, [125I]-DOI saturation binding, and [125I]-DOI GTP 
sensitive high affinity binding in membranes and in autoradiography.  Nonlinear 
regression analysis of [125I]-DOI saturation binding revealed two saturable 
binding sites in membranes from brains of WT mice, with the high affinity site 
representing nearly 10% of the total binding.  In contrast, nonlinear regression 
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analysis of [125I]-DOI saturation binding to membranes from mice expressing the 
VGV isoform reveals only a single, low-affinity site, even though receptor density 
is increased dramatically.  Based on the extended ternary complex model of 
receptor-G-protein coupling (Samama et al., 1993), it is likely that the loss of high 
affinity binding reflects reduced G-protein coupling.  To test this further, [125I]-DOI 
binding was carried out in the presence and absence of a GTP analog.  The 
addition of Gpp(NH)p reduces the binding of [125I]-DOI in brain membranes from 
WT mice, but has no detectable effect on [125I]-DOI binding in membranes from 
VGV/Y mice, suggesting that the G-protein coupling capacity of brain 5HT2C-VGV 
receptors is markedly reduced.  An unexpected finding was the marked increase 
in 5-HT2C receptor density throughout the brains of VGV/Y mice relative to WT, 
suggesting the possibility that Gq/11 protein may become rate-limiting in the case 
of this large increase in receptor density in VGV/Y mice. However, this is the 
normal receptor expression level in one brain structure, the choroid plexus, 
where the receptor functions at a high level (Conn et al, 1986). Early  quantitative 
studies of Milligan (1993) show that  the level of Gq protein  in rat frontal cortex is 
17pmol/mg protein and combined Gq/G11, 25pm/mg protein, which is 5-fold 
higher than receptor density in VGV/Y mice. Furthermore, we have previously 
shown that the levels of Gq and G11 protein are not altered in VGV/y mice 
(Canal et al, 2009).  These results suggest that Gq/11-protein is not rate limiting 
in the brains of VGV/Y and that the reduction in GTP-sensitivity reflects reduced 
coupling capacity in VGV/Y mice.   
 80 
 
Consistent with a reduction in G-protein coupling capacity found in 
membranes prepared from brains of  VGV/Y mice, receptor autoradiography in 
intact brain slices reveals that, although total 3H-mesulergine binding is 
increased, the proportion of GTP-sensitive high affinity [125I]-DOI binding is 
reduced nearly 8-fold in choroid plexus of VGV/Y mice. These experiments 
confirm that the blunted G-protein coupling of the VGV isoform described in cell 
lines is reproduced in a native setting. We conclude therefore that it is valid to 
interpret in vivo increases in the degree of RNA editing of the 5HT2C receptor as 
a loss of function at the cellular level.  An attempt to evaluate the classical 
effector pathway, Gq mediated-PLC activation, was unsuccessful.  Previous 
studies of 5HT2C receptor-mediated PLC activation in rat brain were performed in 
choroid plexus (Conn et al, 1986), but this was not feasible in mice. In mouse 
forebrain, 5HT failed to elicit a PLC signal,  in wild-type or VGV/Y mice. 
Our studies also suggest that changes in the proportion of edited isoforms 
alter the density of 5HT2C receptor binding sites within the brain.  VGV/Y mice, 
solely expressing the VGV isoform, have a 25-fold increase in 5HT2C receptor 
density relative to WT mice, similar to that described by Morabito et al (2007). In 
heterozygous VGV/X mice, the percentage of RNA isoform encoding VGV and 
the density of 5HT2C receptor binding sites is approximately halfway between WT 
and VGV/Y mice.  This gene-dose dependent increase in binding site density 
supports the notion that the increases are not the result of erroneous genetic 
manipulation. In addition, receptor autoradiography suggests that the increased 
expression of 5HT2C receptor in VGV/Y mice does not reflect aberrant distribution 
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of the receptor.  We suggest that the increased density is a compensatory 
response to reduced cellular function of the editing receptor. In support of this 
conclusion, transgenic mice solely expressing the non-edited, highly functional, 
5HT2C-INI receptor have reduced receptor density (unpublished results).   
Although our pharmacological studies in brains of mice expressing the 
VGV isoform document reduced G-protein coupling capacity, the marked 
increase in 5HT2C binding site density may mitigate this diminished cellular signal 
in the intact animal. To investigate the functional consequences in vivo of these 
opposing effects, we employed a behavioral assay of 5HT2C receptor activation.  
5HT2C receptor agonists, such as MK212 have long been known to induce 
hypolocomotion  (Gleason et al., 2001; Gleason and Shannon, 1998; Stiedl et al., 
2007). In ligand binding assays, MK212  is essentially equipotent at rat 5-HT2C 
and 5-HT2B receptors (National Institute of Mental Health's Psychoactive Drug 
Screening Program, Contract # NO1MH32004 (http://pdsp.med.unc.edu/), 
however, recent studies show that  the MK212-elicited hypolocomotion is 
eliminated in 5HT2C receptor null mice (Fletcher et al., 2009), confirming that this 
behavior is a valid measure of in vivo 5HT2C receptor activation in mice.  MK212 
elicits a dose-dependent decrease in locomotor activity in both WT and VGV/Y 
mice, but the sensitivity to MK212 is dramatically increased in VGV/Y mice. This 
observation confirms the work of Kawahara et al (2008),  and importantly shows 
that the marked behavioral sensitization  is reproduced on another background 
strain.  These data suggest that the large increase in receptor density overcomes 
the reduced G-protein coupling of the VGV receptor. Still a third variable, 
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receptor internalization, may play a role given the evidence that RNA editing 
alters the ability of the 5HT2C receptor  to interact with key regulatory molecules, 
G-protein receptor kinase and beta-arrestin (Marion et al, 2004).   
Given emerging evidence suggesting that the 5-HT2C receptor attenuates 
DA release and 5-HT2C receptor antagonists augment the action of dopamine 
releasing agents such as cocaine (Alex and Pehek, 2007; De Deurwaerdere et 
al., 2004; Filip and Cunningham, 2003; Navailles et al., 2003), we examined DA 
turnover as another index of in vivo 5-HT2C receptor function.   5-HT2C receptor 
regulation of DA release is complex, involving direct and indirect pathways; 
microdialysis studies suggest that the mechanism of regulation differs in the 
nigrostriatal versus mesocorticolimbic DA systems (Di Matteo et al., 1999; Di 
Giovanni et al., 2000; see Di Matteo et al., 2008 for review). This may explain the 
regional difference seen in saline-treated VGV/Y mice, where DA turnover in the 
mutant mice is decreased in frontal cortex but not in striatum.  Microdialysis 
experiments combined with direct microinjection would be valuable in pursuing 
this question. The finding that SB206553 increases DA turnover in frontal cortex 
and striatum of VGV/y mice is consistent with the evidence that 5-HT2C receptors 
inhibit DA release in both areas. The ability of SB206553 to increase DA release 
is thought to reflect constitutive activity of the 5-HT2C receptor (De Deurwaerdere 
et al, 2004); however, such an explanation is less plausible in VGV mice since in 
vitro data shows that this isoform is essentially devoid of constitutive activity 
(Berg et al., 2008a; Herrick-Davis et al., 1999; Niswender et al., 1999; Wang et 
al., 2000).  An alternative explanation is suggested by our finding of an increased 
 83 
 
5-HT turnover in VGV mice given SB206553; enhanced release of 5-HT onto the 
up-regulated 5-HT2C receptors may play a role in the SB206553 modulation of 
DA release in VGV mice.  
In summary, in vitro studies in transfected cell lines have shown that RNA 
editing of 5HT2C RNA transcripts profoundly alters the signaling properties of the 
5HT2C receptor protein.  The current studies utilizing genetically modified mice 
solely expressing the most extensively edited isoform of the 5HT2C receptor 
show, for the first time, that the G-protein coupling capacity in the brain is altered, 
i.e., expression of fully edited 5HT2C-VGV receptor isoform within the brain blunts 
receptor-G-protein coupling. We further show that changes in the degree of 
editing significantly alters the density of receptor binding sites within the brain, 
suggesting that the pattern of protein isoforms, and hence the inferred overall 
function of the receptor protein,  may not reflect the pattern of RNA isoforms.  
This conclusion has important implications for human studies of disease-related 
alterations in RNA editing of the 5HT2C receptor, where inferences about protein 
function are based on the profile of RNA edited isoforms.  Our studies further 
emphasize a critical need for a method that differentiates 5HT2C receptor protein 
isoforms in brain tissue.  Until such a method becomes available, clinical and 
laboratory investigations must continue to rely on mRNA isoform distribution to 
infer protein distribution and function. Our studies emphasize the need for 
caution in these interpretations. 
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Chapter IV: Conclusions and New Questions 
 
Summary and Future Directions 
 
 We were able to establish in vitro and in vivo ligand specificity for 5-HT2A 
and 5-HT2C receptors using several techniques. This allowed us to pursue the 
larger goal of examining the in vivo consequences of 5-HT2C receptor pre-mRNA 
editing. To accomplish this we employed genetically modified mice solely 
expressing the 5-HT2C-VGV receptor isoform. Using these mice we show for the 
first time in vivo diminished G-protein coupling in 5-HT2C-VGV receptors that 
mirrors published in vitro data. Our conclusions about G-protein coupling and 
constitutive activity are based on the assumption that the number of constitutively 
active 5-HT2C receptors and/or  5-HT2C receptors in the high-affinity state varies 
directly and positively with overall 5-HT2C receptor density. We have not tested 
this assumption, such an experiment may now be possible if one were to take 
advantage of mice created by Kimura et al. (2009), which over-express 5-HT2C in 
the forebrain. Basal and SB206553 mediated GTPγS binding in WT and 5-HT2C 
over-expressing mice would allow one to determine whether the number of 
constitutively active 5-HT2C receptors is absolute or proportional to overall density  
in vivo. Unlike the in vitro data, we were not able to reproduce the decrease in 
agonist potency in 5-HT2C-VGV receptors. This was due to the fact that we were 
unable to measure a proximal event to 5-HT2C receptor activation, combined with 
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what appear to be compensatory changes in receptor density in all genotypes 
examined. We attempted to measure IP3 formation in both WT and VGV/Y mice, 
and were unable to achieve an adequate signal above noise. This was especially 
surprising given the receptor density in the VGV/Y mice.   
 
Implications for Human Studies 
All studies examining the relationship between 5-HT2C mRNA editing and 
various neurological disorders, such as those summarized in Table 1, use 
predicted mRNA isoform distribution to infer receptor protein distribution. While 
my work shows that this is not ideal, it is the best method currently available. 
 Examining the possible impact of 5-HT2C mRNA editing on human 
neurological disorders at this point is still largely theoretical since we can only 
measure editing profiles directly from post-mortem brain tissue. The data from 
these studies is highly variable as seen in Table 1, and as a result no clear 
conclusions can be made concerning the role of 5-HT2C receptor editing in the 
examined disorders. Furthermore, it is difficult to make a phenotypic 
extrapolation from VGV/Y mice to human beings because the mutant mice 
represent an extreme case where all 5-HT2C receptors are edited. One would 
predict that a human being with such high levels of 5-HT2C receptor editing would 
display altered behavioral patterns, particularly in response to stressors. 
Locomotor control might be affected as well as dopaminergic function in general. 
The patient might be hypoactive, with impaired sympathetic nervous function.   
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 Even if we were able to measure 5-HT2C receptor RNA  isoform distribution in a 
living subject, it is of great importance to know the actual distribution of receptor 
protein when trying to determine the impact of 5-HT2C receptor editing on 
disorders like schizophrenia and depression. We should therefore make a 
concerted effort to  identify alternative markers of 5-HT2C receptor editing, such 
as markers of ADAR activation, that may be present and measurable outside of 
the central nervous system. Without such a method, development of  potential 
therapies targeting editing of the 5-HT2C receptor will not be feasible since it 
would still be impossible to diagnose the  degree of editing with a noninvasive 
procedure that patients will be willing to undergo. Clearly, this is a key challenge 
for the future of drug developments aimed at targeting  5-HT2C receptors. 
 
Increased 5-HT2C-VGV receptor density 
 Possible mechanisms for the increase in 5-HT2C receptor density may 
include: erroneous genetic manipulation, increased mRNA levels, and changes in 
mRNA stability or translation efficiency. The possibility of erroneous genetic 
manipulation is unlikely since the density changes are gene dose dependent. To 
explore this further it is important to look at a different strain of mice. Kawahara et 
al. (2008) developed mice solely expressing the 5-HT2C-VGV receptor isoform on 
the C57B6 background. Since the mice were created by different methods and 
on a different background strain from the mice used in our studies, they 
represent the ideal method for exploring whether the increased 5-HT2C receptor 
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density reported in the current work is the result of erroneous genetic 
manipulation or possibly a compensatory mechanism at work. The Kawahara 
mice show the same increases in agonist and antagonist sensitivity, however, 
Kawahara et al. (2008) claim to only observe an increase in cell-surface 
functional 5-HT2C receptor density in their VGV/Y mice (Figure 35). This 
conclusion is based on the argument that [125I]-DOI selectively labels cell surface 
functional receptors, an assumption that was not tested and is inconsistent  with 
the lipid soluble nature of this amphetamine analog.  Kawahara et al. (2008) also 
observed no significant changes in mRNA level, an observation confirmed by 
Morabito et al. (2009). Membrane saturation binding using the current protocol 
would allow for a direct comparison of density in these two mouse strains, which 
would provide further insight to the mechanism of the density phenotypes 
observed in both strains of mice. Mice expressing only the 5-HT2C-INI receptor 
show decreased receptor density whereas heterozygous VGV/X animals show 
10-fold increased receptor density and at least 10-fold increased agonist 
potency. VGV/Y expressing only the 5-HT2C-VGV receptor, show an even greater 
increase in receptor density, (approximately 25-fold) and an increase in agonist 
potency equal to VGV/X mice, which may be due to floor effects, and the fact 5-
HT2C agonist induced hypolocomotion is not a direct effect of the receptor, but 
more likely the result of 5-HT2C receptor inhibition of dopamine release.  These 
phenotypes point to compensatory gene-dose dependent changes in receptor 
density. This in the case of the VGV/Y mice is sufficient to reverse decreases in 
receptor signaling at the cellular level and markedly augment function when the 
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entire organism is considered.  Complete mRNA analysis of the VGV/X mice is 
necessary to confirm if there is indeed some disruption between RNA and 
translation to protein in these mice. Comprehensive regional analysis of the 5-
HT2C receptor binding site density must be completed to determine whether 
regional differences in 5-HT2C receptor density are maintained. Several brain 
areas have been examined by Morabito et al, and Clinton Canal (personal 
communication), however comprehensive examination of the entire brain is 
necessary.   
 These strains of mice should be further examined to determine the 
developmental timeline of the 5-HT2C receptor overexpression. A density 
sampling should be taken every 7 days between embryonic day 7 and postnatal 
day 84, such a course should allow for observation of the critical period, if any, 
for 5-HT2C receptors in the development of these mice. It is of great importance 
to determine at which point during development this marked increase in receptor 
density occurs, as this could illuminate possible novel roles for the 5-HT2C 
receptor during development.   
 
Inverse agonist / antagonist induced hyperactivity 
 This signaling augmentation in the case of VGV/X and VGV/Y mice was 
not limited to agonist ligand potency. We observed a strange aggressive 
behavior that borders on compulsion accompanied with extreme hyperactivity, 
when mice were injected with a 5-HT2C antagonist /inverse agonist SB206553 
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(Figure 33). In contrast, SB206553 appears to have a hypolocomotive effect in 
WT mice, especially when stereotypic movements are considered (not shown). 
The SB206553 induced hyperactivity cannot be directly accounted for by the 
increase in DA turnover reported in chapter III, as both dopamine D1 and D2 
antagonists potentiate the effects of the 5-HT2C inverse agonist SB206553 
(Figure 34), although this observation more than likely involves complex signaling 
circuits. Dracheva et al. (2009) show increases in 5-HT2C pre-mRNA editing in 
rats with high basal locomotor activity. These rats may be an example of natural 
occurrence of the same phenomena we have observed in these genetically 
modified mice. In order to test that hypothesis, a way of identifying and 
quantifying receptor protein isoforms is necessary. 
 
Opposing locomotor effects of various ligands 
 We also observed unexpected effects of several ligands when VGV/Y 
mice were compared to WT mice including: 8-OH-DPAT (5-HT1A agonist) and 
clonidine (adrenergic α2a agonist) (Figure 36). One possible explanation for  this 
phenomenon is that VGV/Y mice now have markedly increased 5-HT2C receptor 
signaling where there may have been only marginal signaling before, but this is 
just speculation. The change in signaling stoichiometry, in VGV/Y mice 
especially, may have wide ranging effects on a number of neurotransmitter 
systems. This warrants further study into these changes with a possible site 
being the gabaergic interneurons which may modulate serotonin and adrenergic 
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signaling or vice versa. Micro dialysis studies in these mice would be of particular 
interest. 
 
Mice are not rats 
 During the course of this work I noticed that the literature is nearly devoid 
of basic pharmacologic data specific to mice. The assumption is that 
neurotransmitters and ligands will behave in a similar manner as in rats. I found 
that this is not the case, M100907 for example is exquisitely selective for 5-HT2A 
over 5-HT2C in rats. In the strain of mice used in our experiments however, 
M100907 only showed marginal selectivity. There is a wealth of data highlighting 
mouse strain differences in a variety of behaviors, mRNA expression, and 
genetic code; it is not farfetched to imagine that these strain differences may 
extend to receptor protein expression, receptor protein distribution as well as 
receptor protein function.  Some, if not most of the basic science that we take for 
granted and base many assumptions upon must be reconsidered for the mice 
that we now employ on such a widespread basis.  
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Figure 33:  SB206553 Induced Hyperlocomotion 
Exploratory locomotor activity of WT, HET (VGV/X), and VGV (VGV/Y) mice 
after single subcutaneous injection of either, saline,  or 3mg/kg SB206553.  *** 
Significantly different from saline within group, p<0.001. + Significantly different 
from other genotypes, p<0.001  
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Figure 34: DA Receptor Antagonism Potentiates SB206553 Induced 
Hyperlocomotion 
Exploratory locomotor activity (A) and jumping (B) after single subcutaneous 
injection of either saline or SB206553 (3mg/kg) or double subcutaneous 
injections of either haloperidol (1mg/kg) or SCH-23390(0.5mg/kg) followed by 
SB206553 (3mg/kg) 20 minutes later. ** Significantly different from SB206553, 
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Figure 35: Increased Binding in Kawahara Mice: Autoradiography 
  
[125I]-DOI binding in various brain areas in the Kawahara VGV/Y and INI/Y mice. 
The authors attribute the increase in VGV/Y binding to an increase in functional 
receptors which our data refutes.  
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Figure 36: Opposing Effects Of Ligands In Wild Type Vs. VGV/Y Mice Changes In Locomotor Behavior In Wild 
Type And VGV/Y Mice In Response To Treatment With Various Drugs. 
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Conclusions 
  
The current work further illuminates some of the inherent problems in 
present methodologies. Global modification of genes often goes far beyond the 
intended effects. Our knowledge of the roles of many genes during development 
is limited enough that we are unable to predict the effects that these 
modifications will have on intact organisms. Further studies should also include 
analyses of  regional modification of genes, both in terms of developmental 
period and CNS localization. One such study (Kimura et al., 2009) examines 
phenotypic changes in mice overexpressing the 5-HT2C receptor in forebrain. 
They find an increase in anxiety-behavior and reduced activity in a novel 
environment, interestingly we also have observed hypolocomotion in novel 
environments under basal conditions in VGV/Y mice. Similar work will allow for a 
clearer picture of the behavioral and biochemical effects 5-HT2C receptor function 
and dysfunction at a regional level. 
In summary, in vitro studies in transfected cell lines have shown that RNA 
editing of 5HT2C RNA transcripts profoundly alters the signaling properties of the 
5HT2C receptor protein.  The current studies utilizing genetically modified mice 
solely expressing the most extensively edited isoform of the 5HT2C receptor 
show, for the first time, that the G-protein coupling capacity in the brain is altered, 
i.e., expression of fully edited 5HT2C-VGV receptor isoform within the brain blunts 
receptor-G-protein coupling. We further show that changes in the degree of 
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editing significantly alters the density of receptor binding sites within the brain, 
suggesting that the pattern of protein isoforms, and hence the inferred overall 
function of the receptor protein,  may not reflect the pattern of RNA isoforms.  
This conclusion has important implications for human studies of disease-related 
alterations in RNA editing of the 5HT2C receptor, where inferences about protein 
function are based on the profile of RNA edited isoforms.  Our studies further 
emphasize the critical need for a method that differentiates 5HT2C receptor 
protein isoforms in brain tissue.   
.  
  
 97 
 
REFERENCES 
 
Adler CH, Meller E, Goldstein M (1985) Recovery of alpha 2-adrenoceptor 
binding and function after irreversible inactivation by N-ethoxycarbonyl-2-
ethoxy-1,2-dihydroquinoline (EEDQ). Eur J Pharmacol 116:175-178. 
 
Akana SF (2008) Feeding and stress interact through the serotonin 2C receptor 
in developing mice. Physiol Behav 94:569-579. 
 
Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic 
regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320 
. 
Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB (1990) 
Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] 
iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c 
receptors in rat brain. J Pharmacol Exp Ther 255:843-857. 
 
Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, 
Millar RP, Davidson JS, Weinstein H, Sealfon SC (1998) Functional 
microdomains in G-protein-coupled receptors. The conserved arginine-
cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 
273:10445-10453. 
 
Barker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994) Constitutively 
active 5-hydroxytryptamine2C receptors reveal novel inverse agonist 
activity of receptor ligands. J Biol Chem 269:11687-11690. 
 
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. 
Neuropharmacology 38:1083-1152. 
 
Battaglia G, Norman AB, Creese I (1987) Differential serotonin2 receptor 
recovery in mature and senescent rat brain after irreversible receptor 
modification: effect of chronic reserpine treatment. J Pharmacol Exp Ther 
243:69-75. 
 
Benne R, Van den Burg J, Brakenhoff JP, Sloof P, Van Boom JH, Tromp MC 
(1986) Major transcript of the frameshifted coxII gene from trypanosome 
mitochondria contains four nucleotides that are not encoded in the DNA. 
Cell 46:819-826. 
 
Berg KA, Maayani S, Clarke WP (1996) 5-hydroxytryptamine2C receptor 
activation inhibits 5-hydroxytryptamine1B-like receptor function via 
arachidonic acid metabolism. Mol Pharmacol 50:1017-1023. 
 98 
 
 
Berg KA, Harvey JA, Spampinato U, Clarke WP (2005) Physiological relevance 
of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends 
Pharmacol Sci 26:625-630. 
 
Berg KA, Harvey JA, Spampinato U, Clarke WP (2008) Physiological and 
therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C 
receptors for the treatment of depression. Prog Brain Res 172:287-305. 
 
Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP 
(2001) RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-
effector coupling specificity. Br J Pharmacol 134:386-392. 
 
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan 
HW, Eglen RM (1995) The pharmacology and distribution of human 5-
hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 
5-HT2A and 5-HT2C receptors. Br J Pharmacol 115:622-628. 
 
Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. 
Schizophr Res 14:187-202. 
 
Buhot MC (1997) Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 
7:243-254. 
 
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, 
Emeson RB (1997) Regulation of serotonin-2C receptor G-protein 
coupling by RNA editing. Nature 387:303-308. 
 
Cameron DL, Crocker AD (1988) Alkylation of striatal dopamine receptors 
abolishes stereotyped behavior but has no effect on dopamine stimulated 
adenylate cyclase activity. Neurosci Lett 90:165-171. 
 
Canal CE, Mahautmr KC, Cao C, Sanders-Bush E, Airey DC (2009) RNA editing 
of the serotonin 2C receptor and expression of Galpha(q) protein: genetic 
mouse models do not support a role for regulation or compensation. J 
Neurochem 108:1136-1142. 
 
Chang K, Moran J, Triggle D (1970) Mechanism of cholinergic antagonism by N-
ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Pharmacol. Res. Commun. 
2: 63-66. 
 
Chang M, Zhang L, Tam JP, Sanders-Bush E (2000) Dissecting G protein-
coupled receptor signaling pathways with membrane-permeable blocking 
peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial 
cells. J Biol Chem 275:7021-7029. 
 
 99 
 
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) 
and the concentration of inhibitor which causes 50 per cent inhibition (I50) 
of an enzymatic reaction. Biochem Pharmacol 22:3099-3108. 
 
Chou-Green JM, Holscher TD, Dallman MF, Akana SF (2003) Repeated stress in 
young and old 5-HT(2C) receptor knockout mice. Physiol Behav 79:217-
226. 
 
Chou-Green JM, Holscher TD, Dallman MF, Akana SF (2003) Compulsive 
behavior in the 5-HT2C receptor knockout mouse. Physiol Behav 78:641-
649. 
 
Conn PJ, Sanders-Bush E (1986) Agonist-induced phosphoinositide hydrolysis in 
choroid plexus. J Neurochem 47:1754-1760. 
 
De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) 
Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine 
release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-
3241. 
 
Delgado PL, Moreno FA (1998) Hallucinogens, serotonin and obsessive-
compulsive disorder. J Psychoactive Drugs 30:359-366. 
 
Dracheva S, Chin B, Haroutunian V (2008) Altered serotonin 2C receptor RNA 
splicing in suicide: association with editing. Neuroreport 19:379-382. 
 
Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V 
(2003) RNA editing and alternative splicing of human serotonin 2C 
receptor in schizophrenia. J Neurochem 87:1402-1412. 
 
Dracheva S, Patel N, Woo DA, Marcus SM, Siever LJ, Haroutunian V (2008) 
Increased serotonin 2C receptor mRNA editing: a possible risk factor for 
suicide. Mol Psychiatry 13:1001-1010. 
 
Dracheva S, Lyddon R, Barley K, Marcus SM, Hurd YL, Byne WM (2009) Editing 
of Serotonin 2C Receptor mRNA in the Prefrontal Cortex Characterizes 
High-Novelty Locomotor Response Behavioral Trait. 
Neuropsychopharmacology. 
 
Du Y, Davisson MT, Kafadar K, Gardiner K (2006) A-to-I pre-mRNA editing of the 
serotonin 2C receptor: comparisons among inbred mouse strains. Gene 
382:39-46. 
 
Englander MT, Dulawa SC, Bhansali P, Schmauss C (2005) How stress and 
fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 
25:648-651. 
 100 
 
 
Erspamer V (1952) Observations on alleged serotonin- (enteramine)-like nature 
of cerebral pressor substance of Taylor, Page, and Corcoran. AMA Arch 
Intern Med 90:505-512. 
 
Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology 
of hallucinogens. Biochem Pharmacol 75:17-33. 
 
Filip M, Cunningham KA (2003) Hyperlocomotive and discriminative stimulus 
effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) 
receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306:734-743. 
 
Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran 
DP, Jonak GJ, Hartig PR (1999) Messenger RNA editing of the human 
serotonin 5-HT2C receptor. Neuropsychopharmacology 21:82S-90S. 
 
Flaisher-Grinberg S, Klavir O, Joel D (2008) The role of 5-HT2A and 5-HT2C 
receptors in the signal attenuation rat model of obsessive-compulsive 
disorder. Int J Neuropsychopharmacol 11:811-825. 
 
Fletcher PJ, Tampakeras M, Sinyard J, Higgins GA (2007) Opposing effects of 5-
HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on 
premature responding in the five-choice serial reaction time test. 
Psychopharmacology (Berl) 195:223-234. 
 
Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA (2009) 
Characterizing the effects of 5-HT(2C) receptor ligands on motor activity 
and feeding behaviour in 5-HT(2C) receptor knockout mice. 
Neuropharmacology 57:259-267. 
 
Fone KC, Austin RH, Topham IA, Kennett GA, Punhani T (1998) Effect of chronic 
m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C 
receptor levels in the rat. Br J Pharmacol 123:1707-1715. 
 
Frank MG, Stryker MP, Tecott LH (2002) Sleep and sleep homeostasis in mice 
lacking the 5-HT2c receptor. Neuropsychopharmacology 27:869-873. 
 
Gaborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, Hunyady L (2003) The role 
of a conserved region of the second intracellular loop in AT1 angiotensin 
receptor activation and signaling. Endocrinology 144:2220-2228. 
 
Gillespie DD, Manier DH, Sanders-Bush E, Sulser F (1988) The 
serotonin/norepinephrine-link in brain. II. Role of serotonin in the 
regulation of beta adrenoceptors in the low agonist affinity conformation. J 
Pharmacol Exp Ther 244:154-159. 
 
 101 
 
Giorgetti M, Tecott LH (2004) Contributions of 5-HT(2C) receptors to multiple 
actions of central serotonin systems. Eur J Pharmacol 488:1-9. 
 
Gleason SD, Shannon HE (1998) Meta-chlorophenylpiperazine induced changes 
in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors 
in mice. Eur J Pharmacol 341:135-138. 
 
Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD (2001) m-CPP 
hypolocomotion is selectively antagonized by compounds with high affinity 
for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behav 
Pharmacol 12:613-620. 
 
Gott JM, Emeson RB (2000) Functions and mechanisms of RNA editing. Annu 
Rev Genet 34:499-531. 
 
Gozlan H, Laporte AM, Thibault S, Schechter LE, Bolanos F, Hamon M (1994) 
Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
(EEDQ) on various 5-HT receptor binding sites in the rat brain. 
Neuropharmacology 33:423-431. 
 
Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of 
anxiety disorders: more than 30 years of research. Pharmacol Ther 
65:319-395. 
 
Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C (2002) Altered 
editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of 
depressed suicide victims. Neuron 34:349-356. 
 
Hackler EA, Airey DC, Shannon CC, Sodhi MS, Sanders-Bush E (2006) 5-
HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and 
BALB/cJ mice. Neurosci Res 55:96-104. 
 
Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, 
Geyer MA, Powell SB (2009) 5-HT(2A) and 5-HT(2C) receptors exert 
opposing effects on locomotor activity in mice. Neuropsychopharmacology 
34:1958-1967. 
 
Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007) Serotonergic 
drugs : effects on appetite expression and use for the treatment of obesity. 
Drugs 67:27-55. 
 
Hegde SS, Eglen RM (1996) Peripheral 5-HT4 receptors. FASEB J 10:1398-
1407. 
 
Heisler LK, Tecott LH (2000) A paradoxical locomotor response in serotonin 5-
HT(2C) receptor mutant mice. J Neurosci 20:RC71. 
 102 
 
 
Herrick-Davis K, Grinde E, Niswender CM (1999) Serotonin 5-HT2C receptor 
RNA editing alters receptor basal activity: implications for serotonergic 
signal transduction. J Neurochem 73:1711-1717. 
 
Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and 
functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-
554. 
 
Humphrey PP, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT 
receptors. Trends Pharmacol Sci 14:233-236. 
 
Iwamoto K, Nakatani N, Bundo M, Yoshikawa T, Kato T (2005) Altered RNA 
editing of serotonin 2C receptor in a rat model of depression. Neurosci 
Res 53:69-76. 
 
Kawahara Y, Grimberg A, Teegarden S, Mombereau C, Liu S, Bale TL, Blendy 
JA, Nishikura K (2008) Dysregulated editing of serotonin 2C receptor 
mRNAs results in energy dissipation and loss of fat mass. J Neurosci 
28:12834-12844. 
 
Kennett GA, Pittaway K, Blackburn TP (1994) Evidence that 5-HT2c receptor 
antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. 
Psychopharmacology (Berl) 114:90-96. 
 
Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, Blackburn TP 
(1994) In vivo properties of SB 200646A, a 5-HT2C/2B receptor 
antagonist. Br J Pharmacol 111:797-802. 
 
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter 
GS, Forbes IT, Ham P, Blackburn TP (1996) In vitro and in vivo profile of 
SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-
like properties. Br J Pharmacol 117:427-434. 
 
Kimura A, Stevenson PL, Carter RN, Maccoll G, French KL, Paul Simons J, Al-
Shawi R, Kelly V, Chapman KE, Holmes MC (2009) Overexpression of 5-
HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. 
Eur J Neurosci 30:299-306. 
 
Koek W, Jackson A, Colpaert FC (1992) Behavioral pharmacology of antagonists 
at 5-HT2/5-HT1C receptors. Neurosci Biobehav Rev 16:95-105. 
 
Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE (2003) A complex 
signaling cascade links the serotonin2A receptor to phospholipase A2 
activation: the involvement of MAP kinases. J Neurochem 86:980-991. 
 
 103 
 
Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight 
F, Linnoila M, Goldman D (1995) Identification, expression, and 
pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c 
receptor gene (HTR2C). Genomics 27:274-279. 
 
Lentes KU, Hinney A, Ziegler A, Rosenkranz K, Wurmser H, Barth N, Jacob K, 
Coners H, Mayer H, Grzeschik KH, Schafer H, Remschmidt H, Pirke KM, 
Hebebrand J (1997) Evaluation of a Cys23Ser mutation within the human 
5-HT2C receptor gene: no evidence for an association of the mutant allele 
with obesity or underweight in children, adolescents and young adults. Life 
Sci 61:PL9-16. 
 
Leysen JE, Niemegeers CJ, Tollenaere JP, Laduron PM (1978) Serotonergic 
component of neuroleptic receptors. Nature 272:168-171. 
 
Limbird LE (1988) Receptors linked to inhibition of adenylate cyclase: additional 
signaling mechanisms. FASEB J 2:2686-2695. 
 
Loric S, Launay JM, Colas JF, Maroteaux L (1992) New mouse 5-HT2-like 
receptor. Expression in brain, heart and intestine. FEBS Lett 312:203-207. 
 
Martel RR, Berman R, Belleau B (1969) Pharmacology of EEDQ (N-
ethoxycarbonyl-2-ethoxy-1-2-dilhydroquinoline). Can J Physiol Pharmacol 
47:909-912. 
 
McGrew L, Chang MS, Sanders-Bush E (2002) Phospholipase D activation by 
endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 
and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol 
62:1339-1343. 
 
McGrew L, Price RD, Hackler E, Chang MS, Sanders-Bush E (2004) RNA editing 
of the human serotonin 5-HT2C receptor disrupts transactivation of the 
small G-protein RhoA. Mol Pharmacol 65:252-256. 
 
Meller E, Bohmaker K, Goldstein M, Friedhoff AJ (1985) Inactivation of D1 and 
D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-
dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol 
Exp Ther 233:656-662. 
 
Meller E, Goldstein M, Friedhoff AJ, Schweitzer JW (1988) N-ethoxycarbonyl-2-
ethoxy-1,2-dihydroquinoline (EEDQ): a new tool to probe CNS receptor 
function. Adv Exp Med Biol 235:121-136. 
 
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role 
in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry 27:1159-1172. 
 104 
 
 
Millan MJ (2005) Serotonin 5-HT2C receptors as a target for the treatment of 
depressive and anxious states: focus on novel therapeutic strategies. 
Therapie 60:441-460. 
 
Milligan G (1993) Regional distribution and quantitative measurement of the 
phosphoinositidase C-linked guanine nucleotide binding proteins G11 
alpha and Gq alpha in rat brain. J Neurochem 61:845-851. 
 
Morabito MV (2007) Mice Solely Expressing the Fully-edited Isoform of the 
5HT2C Receptor Display Characteristics of Prader-Willi Syndrome. 
Dissertation  
 
Morabito MV, Emeson RB (2009) RNA editing as a therapeutic target for CNS 
disorders. Neuropsychopharmacology 34:246. 
 
Moro O, Lameh J, Hogger P, Sadee W (1993) Hydrophobic amino acid in the i2 
loop plays a key role in receptor-G protein coupling. J Biol Chem 
268:22273-22276. 
 
Navailles S, De Deurwaerdere P, Spampinato U (2006) Clozapine and 
haloperidol differentially alter the constitutive activity of central 
serotonin2C receptors in vivo. Biol Psychiatry 59:568-575. 
 
Navailles S, De Deurwaerdere P, Porras G, Spampinato U (2004) In vivo 
evidence that 5-HT2C receptor antagonist but not agonist modulates 
cocaine-induced dopamine outflow in the rat nucleus accumbens and 
striatum. Neuropsychopharmacology 29:319-326. 
 
Navailles S, Moison D, Ryczko D, Spampinato U (2006) Region-dependent 
regulation of mesoaccumbens dopamine neurons in vivo by the 
constitutive activity of central serotonin2C receptors. J Neurochem 
99:1311-1319. 
 
Navailles S, Moison D, Cunningham KA, Spampinato U (2008) Differential 
regulation of the mesoaccumbens dopamine circuit by serotonin2C 
receptors in the ventral tegmental area and the nucleus accumbens: an in 
vivo microdialysis study with cocaine. Neuropsychopharmacology 33:237-
246. 
 
Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E 
(1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C 
receptor silences constitutive activity. J Biol Chem 274:9472-9478. 
 
Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, 
Stockmeier CA, Emeson RB, Sanders-Bush E (2001) RNA editing of the 
 105 
 
human serotonin 5-HT2C receptor. alterations in suicide and implications 
for serotonergic pharmacotherapy. Neuropsychopharmacology 24:478-
491. 
 
Nonogaki K, Abdallah L, Goulding EH, Bonasera SJ, Tecott LH (2003) 
Hyperactivity and reduced energy cost of physical activity in serotonin 5-
HT(2C) receptor mutant mice. Diabetes 52:315-320. 
 
Olivier B, van Oorschot R, Waldinger MD (1998) Serotonin, serotonergic 
receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int 
Clin Psychopharmacol 13 Suppl 6:S9-14. 
 
Palacios J, Dietl MM (1988) The Serotonin Receptors. 
 
Palacios JM, Mengod G, Vilaro MT, Ramm P (1991) Recent trends in receptor 
analysis techniques and instrumentation. J Chem Neuroanat 4:343-353. 
 
Palacios JM, Raurich A, Mengod G, Hurt SD, Cortes R (1996) Autoradiographic 
analysis of 5-HT receptor subtypes labeled by [3H]5-CT ([3H]5-
carboxamidotryptamine). Behav Brain Res 73:239-243. 
 
Palacios JM, Mengod G, Sarasa M, Vilaro MT, Pompeiano M, Martinez-Mir MI 
(1991) The use of in situ hybridization histochemistry for the analysis of 
neurotransmitter receptor expression at the microscopic level. J Recept 
Res 11:459-472. 
 
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the 
porcine choroid plexus: characterization of a new type of serotonin 
recognition site. Eur J Pharmacol 106:539-546. 
 
Pazos A, Hoyer D, Palacios JM (1984) Mesulergine, a selective serotonin-2 
ligand in the rat cortex, does not label these receptors in porcine and 
human cortex: evidence for species differences in brain serotonin-2 
receptors. Eur J Pharmacol 106:531-538. 
 
Pazos A, Cortes R, Palacios JM (1984) Quantitative receptor autoradiography: 
application to the characterization of multiple receptor subtypes. J Recept 
Res 4:645-656. 
 
Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM (1996) Constitutive 
activation of a single effector pathway: evidence for multiple activation 
states of a G protein-coupled receptor. Mol Pharmacol 49:112-122. 
 
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding 
of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and 
[3H]spiroperidol. Mol Pharmacol 16:687-699. 
 106 
 
 
Price RD, Sanders-Bush E (2000) RNA editing of the human serotonin 5-HT(2C) 
receptor delays agonist-stimulated calcium release. Mol Pharmacol 
58:859-862. 
 
Price RD, Weiner DM, Chang MS, Sanders-Bush E (2001) RNA editing of the 
human serotonin 5-HT2C receptor alters receptor-mediated activation of 
G13 protein. J Biol Chem 276:44663-44668. 
 
Rapport MM, Green AA, Page IH (1948) Serum vasoconstrictor, serotonin; 
isolation and characterization. J Biol Chem 176:1243-1251. 
 
Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, 
Grewal JS, Garnovskaya MN (2001) Multiplicity of mechanisms of 
serotonin receptor signal transduction. Pharmacol Ther 92:179-212. 
 
Ribas C, Miralles A, Busquets X, Garcia-Sevilla JA (2001) Brain alpha(2)-
adrenoceptors in monoamine-depleted rats: increased receptor density, G 
coupling proteins, receptor turnover and receptor mRNA. Br J Pharmacol 
132:1467-1476. 
 
Robinson ES, Dalley JW, Theobald DE, Glennon JC, Pezze MA, Murphy ER, 
Robbins TW (2008) Opposing roles for 5-HT2A and 5-HT2C receptors in 
the nucleus accumbens on inhibitory response control in the 5-choice 
serial reaction time task. Neuropsychopharmacology 33:2398-2406. 
 
Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S (1991) 
Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. 
Biochem Biophys Res Commun 181:1469-1478. 
 
Samama P, Cotecchia S, Costa T, Lefkowitz RJ (1993) A mutation-induced 
activated state of the beta 2-adrenergic receptor. Extending the ternary 
complex model. J Biol Chem 268:4625-4636. 
 
Sanders-Bush E (1988) The Serotonin receptors. Clifton, N.J.: Humana Press. 
 
Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-
dimethoxy-4-methylamphetamine are partial agonists at serotonin 
receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 
246:924-928. 
 
Serretti A, Artioli P, De Ronchi D (2004) The 5-HT2C receptor as a target for 
mood disorders. Expert Opin Ther Targets 8:15-23. 
 
Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ (2001) RNA editing of 
the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6:373-
 107 
 
379. 
 
Stanwood GD, Lucki I, McGonigle P (2000) Differential regulation of dopamine 
D2 and D3 receptors by chronic drug treatments. J Pharmacol Exp Ther 
295:1232-1240. 
 
Stiedl O, Misane I, Koch M, Pattij T, Meyer M, Ogren SO (2007) Activation of the 
brain 5-HT2C receptors causes hypolocomotion without anxiogenic-like 
cardiovascular adjustments in mice. Neuropharmacology 52:949-957. 
 
Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D 
(1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin 
receptors. Nature 374:542-546. 
 
Teitler M, Herrick-Davis K, Purohit A (2002) Constitutive activity of G-protein 
coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem 
2:529-538. 
 
Vane JR (1959) The relative activities of some tryptamine analogues on the 
isolated rat stomach strip preparation. Br J Pharmacol Chemother 14:87-
98. 
 
Vinod KY, Subhash MN, Srinivas BN (2001) Differential protection and recovery 
of 5-HT1A receptors from N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
(EEDQ) inactivation in regions of rat brain. Neurochem Res 26:113-120. 
 
Visiers I, Hassan SA, Weinstein H (2001) Differences in conformational 
properties of the second intracellular loop (IL2) in 5HT(2C) receptors 
modified by RNA editing can account for G protein coupling efficiency. 
Protein Eng 14:409-414. 
 
Wang Q, O'Brien PJ, Chen CX, Cho DS, Murray JM, Nishikura K (2000) Altered 
G protein-coupling functions of RNA editing isoform and splicing variant 
serotonin2C receptors. J Neurochem 74:1290-1300. 
 
Wang DG et al. (1998) Large-scale identification, mapping, and genotyping of 
single-nucleotide polymorphisms in the human genome. Science 
280:1077-1082. 
 
Ward JK, Fox AJ, Barnes PJ, Belvisi MG (1994) Inhibition of excitatory non-
adrenergic non-cholinergic bronchoconstriction in guinea-pig airways in 
vitro by activation of an atypical 5-HT receptor. Br J Pharmacol 111:1095-
1102. 
 
Wenkert D, Schoneberg T, Merendino JJ, Jr., Rodriguez Pena MS, Vinitsky R, 
Goldsmith PK, Wess J, Spiegel AM (1996) Functional characterization of 
 108 
 
five V2 vasopressin receptor gene mutations. Mol Cell Endocrinol 124:43-
50. 
 
Werry TD, Gregory KJ, Sexton PM, Christopoulos A (2005) Characterization of 
serotonin 5-HT2C receptor signaling to extracellular signal-regulated 
kinases 1 and 2. J Neurochem 93:1603-1615. 
 
Winstanley CA, Theobald DE, Dalley JW, Glennon JC, Robbins TW (2004) 5-
HT2A and 5-HT2C receptor antagonists have opposing effects on a 
measure of impulsivity: interactions with global 5-HT depletion. 
Psychopharmacology (Berl) 176:376-385. 
 
Winter J (2009) Hallucinogens as discriminative stimuli in animals: LSD, 
phenethylamines, and tryptamines. Psychopharmacology 203:251-263. 
 
Xie E, Zhu L, Zhao L, Chang LS (1996) The human serotonin 5-HT2C receptor: 
complete cDNA, genomic structure, and alternatively spliced variant. 
Genomics 35:551-561. 
 
Yu L, Nguyen H, Le H, Bloem LJ, Kozak CA, Hoffman BJ, Snutch TP, Lester HA,        
Davidson N, Lubbert H (1991) The mouse 5-HT1C receptor contains eight 
hydrophobic domains and is X-linked. Brain Res Mol Brain Res 11:143-
149. 
 
